[
    {
        "utterance": "Dr. Anna Moore: Sandin at the College of Human Medicine. Uh prior to joining MSU, which was about three years ago, uh my career all my career pretty much went at Massachusetts General Hospital and Harvard Medical School that I joined as postdoctoral fellow and by the time I left I was a professor at Harvard Medical School, professor in radiology. So, uh my personal interest in science is image guided therapy for metastatic cancers. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore is providing relevant facts about her extensive professional background and specific scientific interests, which is a form of sharing knowledge about her expertise.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about Dr. Moore's career and research focus, which helps the team understand her expertise and potential contributions."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um, in the beginning of my career, I used uh iron oxide nanoparticles as contrast agents uh to detect tumors and now we're using them actually as uh carriers as vehicles to deliver therapies and as imaging reporters as well, that's why it's image guided therapy. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore is sharing detailed information about her research expertise, specifically her use of iron oxide nanoparticles as contrast agents and therapy carriers, which is relevant knowledge for a scientific collaboration.",
                "score": 2,
                "score_justification": "The utterance provides accurate and detailed information about her specific research methods and applications, making it a highly useful contribution of knowledge."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So that's it. Um, I mean, I can take tell you more, but I think we should try to keep it short. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The speaker suggests keeping the introductions short, which is a clear attempt to structure the meeting's process and manage time, aligning with structuring process or setting goals.",
                "score": 1,
                "score_justification": "The utterance provides a clear suggestion for managing the meeting's process by setting a goal to keep introductions brief, aligning with a functional contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, um, I I'm just going to go the way I see people on the screen, so no or or no, I do have a list here. Okay, let's just go alphabetically. Benjamin. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The speaker structures the meeting's flow by deciding to proceed alphabetically for introductions, which is a clear process decision.",
                "score": 1,
                "score_justification": "The utterance provides a clear decision on how to structure the process of introductions, which is immediately enacted."
            },
            "Participation Dynamics": {
                "explanation": "The speaker establishes a method for distributing speaking turns ('go alphabetically') and then directly invites Benjamin to contribute.",
                "score": 1,
                "score_justification": "The utterance includes a direct invitation to a specific participant, following a stated method for distributing turns."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Hi. Uh, I'm Ben Benjamin Bartel. I'm assistant professor just started this year at Arizona State University. I work on uh molecular tools for MRI. My goal is to uh non-invasively resolve and manipulate the neuroimmune system. So I do that with a combination of um uh just direct MRI methods uh through um just image analysis and I also build a host of molecular tools using directed evolution, signaling reporters, direct molecular sensors, etc. all for MRI and all in vivo. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares detailed information about his professional background, research focus, goals, and specific methodologies, providing relevant expertise to the team as part of his introduction.",
                "score": 2,
                "score_justification": "The contribution is accurate, highly detailed, and directly useful, offering a comprehensive overview of his expertise that is essential for team understanding and potential collaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: We met yesterday, right? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Dr. Moore asks a direct question, 'We met yesterday, right?', seeking confirmation about a previous interaction with Benjamin Bartelle.",
                "score": 1,
                "score_justification": "It's a clear question seeking specific information, but it's general in the context of the scientific collaboration's immediate task."
            },
            "Relational Climate": {
                "explanation": "Dr. Moore's question 'We met yesterday, right?' acknowledges a prior connection with Benjamin Bartelle, contributing to a friendly and familiar interpersonal tone.",
                "score": 1,
                "score_justification": "It's an explicit acknowledgment of a past interaction, which fosters a positive relational climate, but it's not a strong expression of appreciation or trust."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah, I think we did. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin provides a relevant fact by confirming that he and Dr. Moore met yesterday, directly answering her question.",
                "score": 1,
                "score_justification": "The contribution is a clear, relevant fact, but it is minimal in detail and does not offer deep expertise."
            },
            "Relational Climate": {
                "explanation": "Benjamin's response is a polite and cooperative acknowledgment of Dr. Moore's question, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance is an explicit acknowledgment and a polite response, showing interest in the conversation."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, they screwed up a little bit the facilitators and the group, so I was supposed to be in the other group at the beginning. So, but that's fine. So it's all good to see faces that you've seen before. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares factual information about a logistical error in the meeting's organization, specifically that she was supposed to be in a different group.",
                "score": 1,
                "score_justification": "The information provided is relevant to the current meeting context, explaining her presence in the group, and offers some detail about the error."
            },
            "Relational Climate": {
                "explanation": "Dr. Moore expresses a positive and accepting sentiment about the current group composition, despite a logistical error, which contributes to a supportive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance explicitly expresses a positive sentiment ('it's all good to see faces that you've seen before') that helps maintain a positive social atmosphere."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right. Uh Molly. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Dr. Anna Moore directly invites Molly to speak, which is a behavior that includes a member and balances contributions during the introduction phase of the meeting.",
                "score": 1,
                "score_justification": "The utterance is a clear, direct invitation for a specific person (Molly) to speak, which is a functional contribution to distributing participation."
            }
        }
    },
    {
        "utterance": "Molly Bright: Hi, I'm Molly Bright. I'm at Northwestern in Chicago. Uh, I also do in vivo work with MRI, but with humans. Um, I mostly look at quantifying aspects of the plumbing. So blood flow supplied to the tissue, how that blood flow is regulated or misregulated, um, aspects of oxygen delivery and metabolism. Uh, but I also like to think about how all of that vascular infrastructure supports or doesn't support healthy neural function. So, um, I do a lot of work now in in patients thinking about rehabilitation. So what can we do after something's happened to try to recover and repair both the neural and vascular systems. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Molly Bright provides detailed information about her research background, methodologies (in vivo MRI with humans), and specific areas of expertise, which aligns with providing relevant facts and expertise.",
                "score": 2,
                "score_justification": "The utterance offers accurate, detailed, and directly useful knowledge about her specific research, making it a highly valuable contribution for understanding her expertise in a collaborative setting."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Wonderful. Dylan. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dr. Moore expresses positive acknowledgment and enthusiasm for Molly's introduction by saying \"Wonderful,\" fostering a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The use of \"Wonderful\" is a strong positive acknowledgment, which fosters trust and a positive relational climate."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Moore directly invites Dylan to speak, ensuring that the next team member has an opportunity to contribute during the introductions.",
                "score": 1,
                "score_justification": "It is a clear, direct invitation for the next person to speak, which is functional for distributing participation."
            },
            "Coordination and Decision Practices": {
                "explanation": "Dr. Moore structures the meeting by explicitly calling on the next person, Dylan, to introduce themselves, moving the process forward.",
                "score": 1,
                "score_justification": "The utterance clearly structures the flow of introductions by calling on the next speaker, which is a clear coordination practice."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: Hi, I'm Dylan Burnette. Um, I am an associate professor at Vanderbilt University. I just am just barely on the other side of tenure now. Uh although I still feel like I have like new people problems. Um, but I am a cell biologist by training and so I've been using light microscopes for about 20 years or so, a little bit more unfortunately. Um as I'm getting older. Uh to to study uh the cell skeleton. And so my my lab we kind of took that interest in in the cell skeleton to ask a very simple question. How does a heart grow on a single cell level? Meaning how does a single heart muscle cell physically get bigger? And that is one of the main drivers of our lab. Uh and we do attack that in multiple ways and it occurred to us a few years ago, actually about a year ago now that we could use the same technologies we're using to start mimicking what's happening inside of patients in in a in a uh basically a dish. And so we are now developing uh systems to mimic ischemia and reperfusion injury in our cardiac myos and that's allowed us to start doing screening and I have no idea what I'm doing and it's phenomenal. I have we're having a very good time. Uh and so we are kind of all over the place. We're we're looking at individual sarcomeres and we're looking to find some drugs. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dylan shares detailed information about his professional background, specific research expertise (cell biology, light microscopes, cell skeleton), and current lab projects, including the core question driving his lab and new developments in mimicking patient conditions.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful for other team members to understand his expertise and potential contributions to the collaboration."
            },
            "Relational Climate": {
                "explanation": "Dylan uses enthusiastic language ('it's phenomenal,' 'having a very good time') and lighthearted self-deprecating humor ('new people problems,' 'as I'm getting older') which fosters a positive and open interpersonal tone.",
                "score": 2,
                "score_justification": "His enthusiastic and humorous remarks contribute to a strong acknowledgment and positive atmosphere, fostering trust and curiosity among team members."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. All right, sounds good. Morteza. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Okay. All right, sounds good.' provides a general positive acknowledgment to the previous speaker's introduction, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "This is an explicit acknowledgment showing mild interest, which is more than a token acknowledgment but not a strong expression of trust."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Moore directly invites the next participant, 'Morteza,' to speak, thereby managing the turn-taking and distributing contributions.",
                "score": 1,
                "score_justification": "This is a clear, direct invitation to a specific person, but it is not targeted based on expertise or a specific topic."
            },
            "Coordination and Decision Practices": {
                "explanation": "By calling on 'Morteza,' Dr. Moore is structuring the meeting's process by facilitating the next introduction in the sequence.",
                "score": 1,
                "score_justification": "This action clearly structures the flow of the meeting (introductions), representing a clear process step being enacted."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Hi, my name is Morteza Mahmoudi and uh I'm an assistant professor at Michigan State University. My work is uh focused on nanomedicine and regenerative medicine and basically we use imaging technique to basically probe nanoparticles. if we use them for like therapeutic approaches like MRI approaches, if we use like magnetic based nanoparticles. Uh, but uh most importantly we try to understand what happens at the surface of nanoparticles. So for that purpose we combine cryo transmission electron microscopy and uh 3D constructed imaging model to basically see the 3D structure of the nanoparticles and how they interact with proteins and at the larger scale how they interact with different cell types and what are their uh trafficking inside the cells. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Morteza shares detailed information about his research focus on nanomedicine and regenerative medicine, including specific techniques like cryo transmission electron microscopy and 3D imaging models, and his research questions about nanoparticle interactions and trafficking.",
                "score": 2,
                "score_justification": "Morteza provides accurate, detailed, and directly useful knowledge about his expertise, methodologies, and specific research questions, which is highly relevant for understanding his potential contributions to the team."
            },
            "Relational Climate": {
                "explanation": "The utterance begins with a standard greeting, 'Hi, my name is Morteza Mahmoudi,' which serves as a basic social acknowledgment.",
                "score": 0,
                "score_justification": "The opening 'Hi' is a standard, polite greeting that functions as a token acknowledgment without expressing strong positive or negative interpersonal tone."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Paris. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Morteza explicitly invites Paris to speak by calling their name, thereby including them in the participation.",
                "score": 1,
                "score_justification": "It is a clear and direct invite to a specific person, but not tied to their expertise or a specific topic."
            },
            "Coordination and Decision Practices": {
                "explanation": "Morteza structures the meeting's workflow by indicating who should speak next in the round of introductions, taking on a temporary facilitation role.",
                "score": 1,
                "score_justification": "It is a clear act of structuring the process of introductions, but not an elaborate goal setting or decision."
            }
        }
    },
    {
        "utterance": "Paris Perdikaris: Hello everyone. So my name is Paris Perdicarris and I'm assistant professor at the Department of Mechanical Engineering at the University of Pennsylvania. Um, my background actually is in applied mathematics and my work is focused on developing machine learning methods and computational tools for modeling and simulation of physical and biological systems. I think most relevant to this meeting in some is some work I'm pursuing on physics based filtering of um uh in vivo MRI uh with a focus on 4D flow MRI and reconstructing blood flow and measurements in a way that the underlying physics is satisfied, so principles like mass and momentum conservation and then using those principles to infer auxiliary measurements that um cannot be measured by imaging such as blood pressure, uh shear stresses, um uh and so forth. So the idea there is really to understand the role of hemodynamics in determining organ function and uh you know, predicting biomarkers that are relevant to cardiovascular disease. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker shares detailed and relevant information about their academic background, research focus, specific methodologies (e.g., machine learning, physics-based filtering of 4D flow MRI), and the application domain (hemodynamics, cardiovascular disease biomarkers), which is directly useful knowledge for the team.",
                "score": 2,
                "score_justification": "The speaker provides accurate, detailed, and directly useful knowledge about their expertise, specific research methods, and the relevance of their work to potential collaboration topics, effectively establishing their contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Wonderful, Lisa. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Wonderful, Lisa' expresses positive acknowledgment and enthusiasm towards Lisa, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit praise ('Wonderful') which is a clear positive social interaction, but it is general and not elaborated to foster deeper trust or curiosity."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: Hi everyone, I'm Lisa Poulikakos. I'm an assistant professor at UC San Diego. My research works on nanophotonics, so the study and manipulation of light at the nanoscale. Um, and some questions I'm really interested in is how can we scale down the complex manipulation of light. So a lot of these really sophisticated imaging techniques using state of the art nano optics can actually be realized on a single optical surface, which is then uh nano patterned in intricate ways and then can really be easily deployed in a variety of in vivo and ex vivo applications. Um and some questions that I find interesting um recently are how can we uh enhance polarized light matter interactions to learn more about the structural properties of molecules or tissues, for example. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Lisa shares her research background in nanophotonics, detailing her work on scaling down light manipulation for imaging and enhancing light-matter interactions, which provides relevant expertise to the group.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful knowledge, as she elaborates on her specific research area, methods, and questions, which helps the team understand her potential contributions."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, thank you. Crystal. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dr. Anna Moore expresses gratitude ('thank you') to the previous speaker, which explicitly acknowledges their contribution.",
                "score": 1,
                "score_justification": "The utterance provides explicit thanks, which is a clear contribution to a positive relational climate, but it's not a strong acknowledgment that fosters deep trust or curiosity."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Anna Moore directly invites 'Crystal' to speak, thereby including her in the conversation and structuring participation.",
                "score": 1,
                "score_justification": "The utterance is a direct invitation to a specific individual, which is a clear contribution to managing participation, but it is not tied to specific expertise or a topic."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: Hi everyone. Uh my name is Crystal Rogers and I am an assistant professor at UC Davis. I am a developmental uh molecular and cell biologist and my research focuses on on understanding um the roles of transcription factors and cell cell adhesion molecules in regulating the process of the epithelial to transition. So I study neural crest cells um and those cells are really dynamic and they make a lot of different um adult tissues, but probably more relevant to this group, uh all of the molecular mechanisms that allow those cells to undergo EMT are then re uh reused by cancer cells to metastasize. And so what we are doing in my lab is really trying to get at the basal function of the proteins that allow these cells to undergo EMT and to migrate and differentiate and then um at least my postdoc is really interested in trying to define whether those functions um are conserved in disease states. And so we do a lot of fixed and live imaging of these cells to get at um how the collective migration works um and and the paths that these cells take and then um hopefully how that's affected by perturbations of these different proteins. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Crystal shares detailed information about her scientific background, specific research focus on neural crest cells and EMT, lab activities, and methodologies, explicitly connecting it to potential relevance for the group.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about her expertise, research focus, and methods, which is highly relevant for a scientific collaboration meeting."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Very, very interesting. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Very, very interesting' expresses strong enthusiasm and acknowledgment of Crystal's research, fostering a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The utterance provides strong positive acknowledgment and enthusiasm for the shared research, which fosters a positive relational climate."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Right in line with what we're doing too, so okay. Uh Mark. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "The speaker synthesizes Crystal's research by explicitly stating its alignment and relevance to the group's ongoing work.",
                "score": 1,
                "score_justification": "The utterance provides an accurate, albeit brief, integration of Crystal's contribution by connecting it to the team's work."
            },
            "Relational Climate": {
                "explanation": "The speaker expresses positive acknowledgment and support for Crystal's contribution by highlighting its relevance to the group's work.",
                "score": 1,
                "score_justification": "The utterance provides an explicit positive comment acknowledging the relevance of Crystal's work."
            },
            "Participation Dynamics": {
                "explanation": "The speaker explicitly invites Mark to contribute, indicating a shift in speakers.",
                "score": 1,
                "score_justification": "The utterance provides a clear and direct invitation for a specific team member to speak."
            }
        }
    },
    {
        "utterance": "mark sellmyer: that we can't do at this point. And another the other component is really around imaging gene and cell therapies and if we can image it and control it then perhaps we can get into that, you know, positive feedback loop of modulating something in the therapy and then seeing how that changes. So, um, thanks. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark shares his expertise by describing his research focus on 'imaging gene and cell therapies' and the concept of a 'positive feedback loop' for modulating therapy, providing relevant details about his work.",
                "score": 2,
                "score_justification": "Mark provides detailed and relevant information about his research focus and methodology, which is directly useful for understanding potential collaborations."
            },
            "Idea Management": {
                "explanation": "Mark introduces the idea of imaging gene and cell therapies and the concept of a positive feedback loop for modulating therapy, which are potential research directions for the group.",
                "score": 1,
                "score_justification": "Mark presents a clear research area and concept, providing a direction for potential collaborative ideas."
            },
            "Relational Climate": {
                "explanation": "Mark concludes his statement with 'thanks,' expressing a positive and polite interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance includes an explicit 'thanks,' which is a clear positive relational gesture."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh I just don't want to mispronounce your name. Sixian, Sixian, is that the right way to say it? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Dr. Moore asks for clarification on the pronunciation of Sixian's name, which is a precise and targeted question to obtain specific information.",
                "score": 2,
                "score_justification": "The question is precise and highly relevant for correctly addressing a new participant, moving the interaction forward respectfully."
            },
            "Relational Climate": {
                "explanation": "Dr. Moore expresses a desire to correctly pronounce the participant's name, demonstrating respect and fostering a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The explicit effort to correctly pronounce the name shows strong consideration and respect, which helps build trust and a positive climate."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Moore directly addresses Sixian by name and asks for clarification, which serves as a direct invitation for him to speak and introduce himself.",
                "score": 1,
                "score_justification": "Dr. Moore directly invites Sixian to speak by addressing him, but the invitation is general and not yet tied to his specific expertise."
            }
        }
    },
    {
        "utterance": "Sixian You: Uh, yeah, close enough. So my name is uh Sixian You. Yes. Uh, so I'm assistant professor in electrical engineering at MIT. I just started uh this March. Uh, I did my PhD in UIUC uh in label free microscopy. And then I did my uh postdoc in Berkeley in computational imaging. So my new lab uh the goal is to see how to use optics and algorithms to enable breakthroughs in biomedicine, especially the clinical adoption of microscopy in different uh biomedical situations like early cancer diagnosis, image guided therapies and neuroimaging. So I'm very interesting this session uh the reason I've never done anything like image guided therapies before, but uh I'm very curious how can I contribute? How can I use label free imaging, how can I use optics and algorithms to enable point of procedure diagnosis uh or point of procedure real time monitoring of the therapeutic process. Uh, what role would a resolution of cellular dynamics mean in the in the process of imaging guided therapies. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker asks precise questions like \"How can I contribute?\" and \"How can I use label free imaging... to enable point of procedure diagnosis...\" to understand how their expertise fits into the collaboration.",
                "score": 2,
                "score_justification": "The questions are specific to their expertise and the meeting's topic, aiming to find concrete ways to contribute."
            },
            "Knowledge Sharing": {
                "explanation": "The speaker shares detailed information about their academic background, research areas (label-free microscopy, computational imaging), and the goals of their new lab, providing relevant expertise.",
                "score": 2,
                "score_justification": "The speaker provides a comprehensive and detailed overview of their relevant expertise, which is directly useful for understanding potential contributions to the collaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Thank you so much. And then there's other people who are not on my list. I don't know if you guys want to introduce yourself. Um. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dr. Anna Moore explicitly thanks Sixian You for their introduction, demonstrating acknowledgment and support.",
                "score": 1,
                "score_justification": "The utterance provides explicit thanks, which is a clear positive contribution to the relational climate."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Anna Moore invites other unlisted participants to introduce themselves, aiming to include them in the meeting.",
                "score": 1,
                "score_justification": "The utterance provides a direct invitation for other participants to introduce themselves, aiming to include them in the meeting."
            }
        }
    },
    {
        "utterance": "Arne Bakker (he/him) | CZI: So I'll just briefly say hi if that's okay just to you know who I am. I'm Arne Bakker, I'm at CZI, I'm the director of meetings and community um and so me and my team we host meetings like this about 15 to 20 times a year for the the the the scientists that CZI funds to really uh hope to encourage collaboration and sharing of knowledge. Um and I have a PhD in immunology and did my postdoc at Berkeley and my PhD at the Netherlands Cancer Institute in Amsterdam uh hence my interest in this topic. Uh but I'm mostly here to observe so I'm going to probably throw my camera off and and listen in but uh looking forward to hearing the conversation. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Arne shares relevant facts about his identity, his organization's mission to foster collaboration and knowledge sharing, and his academic background and expertise, which are directly useful for understanding his role and interest.",
                "score": 2,
                "score_justification": "This contribution is accurate, detailed, and directly useful knowledge, providing a comprehensive introduction of himself and his organization's relevant activities."
            },
            "Relational Climate": {
                "explanation": "Arne fosters a positive interpersonal tone by stating CZI's aim to 'encourage collaboration and sharing of knowledge' and expressing that he is 'looking forward to hearing the conversation.'",
                "score": 1,
                "score_justification": "This is an explicit expression of interest and a general positive statement about the meeting's purpose, contributing to a good climate."
            },
            "Participation Dynamics": {
                "explanation": "Arne explicitly clarifies his role in the meeting by stating he is 'mostly here to observe' and will 'listen in,' setting expectations for his level of contribution.",
                "score": 1,
                "score_justification": "This is a clear statement about his intended participation, which helps manage expectations for the group."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh Sandra, do you want to say a couple of words? ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "The utterance directly invites a specific individual, Sandra, to speak, which is a behavior that includes members and balances contributions.",
                "score": 1,
                "score_justification": "This is a clear, direct invitation to a specific person, but it is not explicitly tied to their expertise or a particular topic beyond general introductions."
            }
        }
    },
    {
        "utterance": "Sandra Laney - Walder Foundation: Yeah, just really quickly. I'm I'm a guest. I'm from the Walder Foundation based in the Chicago region um and I'm the senior program uh director for science innovation. So really just here as an observer looking forward to hearing the conversation. I also will probably shut my camera off and just participate as a butterfly on the wall. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Sandra shares relevant facts about her affiliation (Walder Foundation), her role (senior program director for science innovation), and her purpose for attending the meeting (observer), which is accurate, detailed, and useful knowledge for the team.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful, providing concrete information about her background and role in the meeting."
            },
            "Relational Climate": {
                "explanation": "Sandra expresses a positive interpersonal tone by stating she is 'looking forward to hearing the conversation,' indicating interest in the discussion.",
                "score": 1,
                "score_justification": "The utterance provides an explicit expression of interest in the conversation, which is a clear positive contribution to the relational climate."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Um so um I guess the first thing we need to do is to select a person uh who's going to be recording uh all the great thoughts that hopefully come come out of this meeting. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The utterance structures the meeting's workflow by identifying the first task and setting a goal to select a person for recording, which aligns with structuring process and setting goals.",
                "score": 1,
                "score_justification": "The utterance clearly states a procedural goal for the meeting, providing a clear agenda item but without full detail or immediate enactment of the decision."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I did it last time, so I'm not going to do it this time, but it was actually very fun. So somebody else should have that opportunity. You're just writing down sketches and then everybody likes you because you did the work. So. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Benjamin declines to take on the recording role again but actively encourages others to participate by highlighting the positive aspects of the task, contributing to the distribution of contributions.",
                "score": 1,
                "score_justification": "The speaker clearly states his non-availability for a task and encourages others to take it, contributing to the distribution of participation."
            },
            "Relational Climate": {
                "explanation": "Benjamin uses positive framing ('very fun,' 'everybody likes you') to encourage others to take on the recording role, fostering a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The speaker uses elaborated positive framing to make a task appealing, which strongly fosters a positive relational climate and encourages participation."
            },
            "Coordination and Decision Practices": {
                "explanation": "Benjamin responds to the need to select a recorder by stating his unavailability and encouraging others, contributing to the team's process of organizing and deciding on a task.",
                "score": 1,
                "score_justification": "The speaker provides a clear input regarding a task assignment, contributing to the team's process of organizing and deciding."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: That is very true Ben. So Ben did it the last time yesterday and he did an an amazing job. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance explicitly acknowledges Benjamin's previous contribution and praises his performance, fostering a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The utterance provides strong, explicit praise ('amazing job') for a team member's past work, which fosters a positive relational climate and encourages future contributions."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah' serves as a token acknowledgment in response to Dr. Moore's previous statement, 'That is very true Ben. So Ben did it the last time yesterday and he did an an amazing job.'",
                "score": 0,
                "score_justification": "This is a token acknowledgment, which is explicitly defined as a 0-score contribution for Relational Climate."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: And uh as uh Andrew pointed out, you don't need to fill up that slide uh right away because I guess I guess there's some I don't know, interference or something. My internet is not working very great either. So uh you can just write it down somewhere and then transfer it on the slide. So Ben, do you do you want to just basically give people like a couple of ideas how to do that? So they because they they will look a little bit scared. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The speaker provides a procedural adjustment for filling out the slide due to internet issues, suggesting writing notes down first, which structures the team's workflow.",
                "score": 2,
                "score_justification": "The utterance offers a clear, effective, and actionable solution to a technical problem, enabling the team to continue with the task effectively."
            },
            "Participation Dynamics": {
                "explanation": "The speaker directly invites Ben to share his expertise on how to perform the task, building on his previous successful experience mentioned in the prior conversation.",
                "score": 2,
                "score_justification": "This is a targeted invitation to a specific team member, leveraging his known expertise from previous experience to guide others."
            },
            "Relational Climate": {
                "explanation": "The speaker expresses empathy for other team members who might be 'scared' about the task, fostering a supportive and understanding interpersonal tone.",
                "score": 2,
                "score_justification": "The utterance demonstrates strong empathy and concern for the team's comfort, which helps foster trust and a positive relational climate."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Sure. We're um so you know, we all had a conversation yesterday that when people would make a point, they come in and say like, I don't know, we could one thing was we collect more data than we use these days. And so I just wrote that down. Somebody else said, you know, I'm involved in really these large scale projects and we try to collect data for other people. Like, okay, well, put those things together and I just started cluster together the the main points people were making. And they ended up being in about three general categories. And so at the end, I was like, hey everybody, things kind of went into these three categories. That's great. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares his expertise by detailing the process he used in a previous meeting to collect and categorize points made by others into three general categories, in response to Dr. Moore's request for ideas on how to do that.",
                "score": 2,
                "score_justification": "This is accurate, detailed, and directly useful knowledge, providing a concrete method for organizing discussion points as requested by Dr. Moore."
            },
            "Integration Practices": {
                "explanation": "Benjamin describes how he summarized and synthesized contributions from a previous meeting by clustering the main points people were making into three general categories.",
                "score": 2,
                "score_justification": "This is a balanced and comprehensive description of how he integrated multiple inputs from a past discussion, providing a clear method for synthesizing information."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh we we we sure did. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Uh we we we sure did' serves as a simple, affirmative acknowledgment of Benjamin's preceding statement about a past conversation and the categorization of ideas.",
                "score": 0,
                "score_justification": "This is a token acknowledgment, confirming a shared past event without further elaboration or strong positive sentiment, fitting the 'Vague/minimal contribution' criteria."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It's great to be appreciated. I'm just trying to sell it. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin expresses appreciation for being acknowledged ('It's great to be appreciated') and uses a lighthearted, self-deprecating phrase ('I'm just trying to sell it') to maintain a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance explicitly expresses appreciation and uses humor, contributing to a positive relational climate, which is a clear contribution with some detail."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Thank you, appreciate that too. All right, so any volunteers? ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dr. Moore expresses appreciation ('Thank you, appreciate that too') in response to Benjamin's previous comment, fostering a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit thanks and appreciation, contributing positively to the interpersonal tone."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Moore invites team members to contribute by asking 'any volunteers?', aiming to distribute tasks or roles.",
                "score": 0,
                "score_justification": "The utterance offers a generic invitation for participation without targeting specific individuals or expertise."
            }
        }
    },
    {
        "utterance": "Sixian You: That is what. I can do it. I'm a newbie in image guided therapies anyway, so I I'm here to absorb and learn. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Sixian volunteers for a task by stating \"I can do it\" in response to a call for volunteers, which directly contributes to the team's process of assigning responsibilities.",
                "score": 1,
                "score_justification": "Sixian clearly takes on a task in response to a call for volunteers, which is a functional step in coordinating team activities."
            },
            "Knowledge Sharing": {
                "explanation": "Sixian shares relevant information about their current level of expertise (\"I'm a newbie in image guided therapies\") and their motivation to learn, which informs the team about their background.",
                "score": 1,
                "score_justification": "The statement provides a clear, relevant fact about Sixian's expertise level, which is a functional contribution to the team's understanding of its members."
            },
            "Relational Climate": {
                "explanation": "Sixian expresses a positive and collaborative attitude by stating a willingness to \"absorb and learn,\" which fosters a supportive and open interpersonal tone within the team.",
                "score": 2,
                "score_justification": "The utterance explicitly conveys a strong positive attitude and eagerness to learn, which significantly contributes to fostering trust and a positive relational climate."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Sixian, thank you so much. That's uh great. So it's actually up to you. You can write, you know, write in the slide if you want. It's up to you or on the, you know, piece of paper on or on the computer screen and then. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dr. Moore expresses strong appreciation and enthusiasm by saying 'thank you so much' and 'That's uh great' to Sixian for volunteering, which fosters a positive interpersonal tone.",
                "score": 2,
                "score_justification": "Dr. Moore provides strong acknowledgment and enthusiasm for Sixian's contribution, fostering trust and a positive climate."
            },
            "Coordination and Decision Practices": {
                "explanation": "Dr. Moore provides clear options and guidance to Sixian on how to perform the task they volunteered for ('You can write... in the slide if you want. It's up to you or on the... piece of paper... or on the computer screen'), structuring the process.",
                "score": 2,
                "score_justification": "Dr. Moore offers explicit guidance and options for task execution, demonstrating effective coordination linked to a specific task."
            }
        }
    },
    {
        "utterance": "Sixian You: Uh, yes. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Uh, yes.' is a very short, minimal response that does not explicitly demonstrate any of the defined coding behaviors.",
                "score": 0,
                "score_justification": "As per the guidelines, utterances with only a few words like 'yep', 'umm', 'I see' should be coded as 'None'."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: No, no, no, it's slide 42. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore provides the specific and accurate slide number (42), which is a directly useful piece of knowledge for Sixian to proceed with the task of writing on the correct slide.",
                "score": 2,
                "score_justification": "The utterance provides accurate, specific, and directly useful knowledge that corrects a potential misunderstanding and enables the team member to proceed effectively."
            }
        }
    },
    {
        "utterance": "Sixian You: 42. Okay. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Sixian You's utterance '42. Okay.' serves as a token acknowledgment, confirming receipt of the slide number mentioned by Dr. Anna Moore.",
                "score": 0,
                "score_justification": "The utterance is a simple 'Okay,' which is explicitly listed as an example of a token acknowledgment, providing minimal functional contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, it's the recovery slide or is the original slide? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker is asking a precise question to clarify which version of the slide ('recovery slide' or 'original slide') should be used, which directly seeks specific information to resolve an ambiguity.",
                "score": 2,
                "score_justification": "The question is precise and targeted, offering specific options to clarify which slide version is correct, thus moving the team forward by seeking highly relevant information."
            }
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Whichever one is for our room. It doesn't matter what number slide it is. If it's the one for 2.3. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Molly clarifies the process for identifying the correct slide by shifting the focus from slide numbers to its intended purpose for their specific room/group, which helps in coordinating shared materials.",
                "score": 1,
                "score_justification": "The utterance provides a clear and detailed criterion for identifying the correct slide, which is a functional contribution to coordinating the team's materials."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So we're saying there's versions of the document and we should use the one that doesn't say recovery somehow just so if I understood correctly. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "Lisa summarizes the team's discussion about using a specific document version (\"So we're saying there's versions of the document and we should use the one that doesn't say recovery somehow\") to ensure her understanding aligns with the group's.",
                "score": 1,
                "score_justification": "Lisa provides an accurate summary of a specific point from the discussion, which is a clear contribution but not a comprehensive integration for closure."
            },
            "Information Seeking": {
                "explanation": "Lisa explicitly asks for confirmation of her understanding of the discussed document version (\"just so if I understood correctly\"), which is a precise question to clarify information.",
                "score": 2,
                "score_justification": "Lisa asks a precise and targeted question to confirm her understanding of a specific point, which is highly relevant for moving the discussion forward."
            }
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Got it. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Got it.' explicitly acknowledges understanding of the previous speaker's clarification regarding the correct document version to use.",
                "score": 1,
                "score_justification": "It is a clear acknowledgment of understanding, which is more than a token response but not a strong expression of praise or enthusiasm."
            }
        }
    },
    {
        "utterance": "Sixian You: That makes sense. Okay. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'That makes sense. Okay.' expresses acknowledgment and understanding of the previous discussion about the document version, fitting the focus on interpersonal tone and expressing acknowledgment.",
                "score": 1,
                "score_justification": "The utterance provides a clear acknowledgment of understanding, which is more than a token acknowledgment but not a strong, trust-fostering statement."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I have a slide that doesn't say recovery. Well, okay. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Anna Moore provides the relevant information that she has a slide that does not contain the term 'recovery,' directly addressing the team's prior discussion about document versions.",
                "score": 1,
                "score_justification": "The utterance offers a clear and relevant fact that contributes to the ongoing discussion, but it is not highly detailed or elaborated."
            }
        }
    },
    {
        "utterance": "Sixian You: Okay. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Okay.' serves as a minimal acknowledgment of the previous speaker's statement, aligning with the definition of Relational Climate as expressing acknowledgment.",
                "score": 0,
                "score_justification": "This is a token acknowledgment, which fits the criteria for a score of 0 in Relational Climate."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: already entered her name. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The utterance confirms the completion of an administrative task ('already entered her name'), which is a clear update on a process-related action within the meeting's workflow.",
                "score": 1,
                "score_justification": "It's a clear statement about a process-related action, providing a functional update on a task."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, you can just do that. Okay, great, excellent. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The speaker expresses positive acknowledgment and enthusiasm with phrases like 'Okay, great, excellent' in response to a previous action of entering a name.",
                "score": 1,
                "score_justification": "The utterance provides explicit positive acknowledgment and praise ('great, excellent'), which is a clear contribution to the relational climate."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right, so here we go. Um from models to humans. Um so basically the question is we have uh a lot of uh drugs in the pipeline in in uh petri dishes in the labs uh that were beautifully uh when you seed the cells, you know, and then you sprinkle the drug, cells dead, all good. Uh, totally different issues when you start injecting something in the body, whether it's a mouse, a rat or or human. Well, you can't inject in the human before you inject in the mouse and the rat but anyway, so the big issue is how do you how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome? Uh, and the biggest question, I guess, you all know that it takes about 10 years to get something from the bench to to being somewhat approved. Not even fully approved, but somewhat approved. 10 years, uh, tens of millions, sometimes hundred millions of dollars. Just just something has to something has to be done about that. So, um, so we're here to to solve this problem today. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker provides detailed background information about the challenges in drug development, including the difference between in vitro and in vivo, the time (10 years), and cost (tens to hundreds of millions of dollars) involved.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and highly relevant knowledge about the drug development process, including specific timelines and costs, which is crucial for framing the problem."
            },
            "Information Seeking": {
                "explanation": "The speaker explicitly asks 'how do you how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome?', surfacing key gaps that the team needs to address.",
                "score": 2,
                "score_justification": "The questions posed are precise, targeted, and highly relevant, directly identifying the core biological barriers and delivery challenges the team needs to address."
            },
            "Coordination and Decision Practices": {
                "explanation": "The speaker structures the discussion by explicitly stating the purpose of the meeting, 'we're here to to solve this problem today,' and framing the 'big issue' and 'biggest question' as the focus.",
                "score": 2,
                "score_justification": "The utterance explicitly states the team's goal to solve the problem today and clearly frames the central issues, effectively structuring the meeting's purpose."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yes. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Yes' is a minimal contribution and does not explicitly demonstrate any of the defined behaviors in the codebook.",
                "score": 0,
                "score_justification": "The utterance is too brief and vague to be scored against any specific code."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): So as a mechanistic scientist, I just want to to bring up this, you know, start at the base level basically, that the issue or one of the big issues that we have with this is that the con. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Crystal introduces a fundamental issue related to the problem of drug development, signaling her intent to 'bring up this' and 'start at the base level'.",
                "score": 1,
                "score_justification": "The utterance clearly introduces an idea/issue, but it is cut off before the full elaboration, making it a clear but not fully detailed contribution."
            },
            "Knowledge Sharing": {
                "explanation": "Crystal explicitly states her role as a 'mechanistic scientist' to frame the upcoming discussion, sharing her expertise and perspective on the core issues.",
                "score": 1,
                "score_justification": "She provides relevant context by stating her expertise and indicating she will share knowledge from that viewpoint."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): of these processes or or you know, pathways, they're not even conserved between people, much less species. And so we have a really uh significant issue if we focus on one model organism and there's no confirmation of of pathways, molecular pathways for treatments. And so as you mentioned, something can be targeted in the mouse and never works in the human and doing research with model organisms, even closely related ones, I can tell you that even within the same order, there's no guarantee that these species have um kind of the same there's not the mechanistic processes aren't the same. So I think we need a lot more basic level research to really define what the conserved pathways that drive these processes of say EMT, cell migration, metastasis are, um before we can jump to treating humans and and we have to have both of those at the same time in my opinion. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Crystal shares her expertise as a mechanistic scientist, detailing the issue of non-conserved pathways between species and people, which limits the effectiveness of model organisms in drug development.",
                "score": 2,
                "score_justification": "The contribution provides specific, detailed biological facts and their implications, directly addressing the problem at hand."
            },
            "Idea Management": {
                "explanation": "Crystal introduces the idea that more basic level research is needed to define conserved pathways before effectively treating humans.",
                "score": 2,
                "score_justification": "The idea is clearly stated, elaborated with reasoning about the biological challenges, and proposes a specific, actionable research focus."
            },
            "Evaluation Practices": {
                "explanation": "Crystal evaluates the current practice of focusing on single model organisms as having a 'significant issue' due to non-conserved pathways, which hinders effective human treatment.",
                "score": 2,
                "score_justification": "The evaluation provides a clear critique of current practices with detailed biological reasoning and implicitly suggests a more effective alternative."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Could I ask a follow up on on Crystal's comment? So I come from the optics and physics side so I'm just learning recently about the biological model making and so on. So how much do some of these relatively recent um 3D physiologically relevant cell culture models help? So so making basically um so so from you know, my reading and talking to some collaborators it seems like people are getting better at making in vitro models of of the human also for drug testing for example. So does that help maybe avoid some animal models or is that completely often brings along a whole other set of challenges? What's kind of the latest um state of the art there? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Lisa asks precise, targeted questions about the utility and challenges of 3D physiologically relevant cell culture models, directly following up on Crystal's discussion about animal models and species differences.",
                "score": 2,
                "score_justification": "The questions are precise, targeted, and highly relevant to the ongoing discussion, seeking specific information to move the conversation forward effectively."
            },
            "Knowledge Sharing": {
                "explanation": "Lisa shares her disciplinary background and some general knowledge she has acquired about in vitro models, providing context for her subsequent questions.",
                "score": 1,
                "score_justification": "The contribution is relevant and provides some detail about her learning and observations, framing her inquiry."
            },
            "Integration Practices": {
                "explanation": "Lisa explicitly links her questions to Crystal's previous comment, ensuring continuity of the discussion and building upon the prior contribution.",
                "score": 1,
                "score_justification": "It accurately connects her contribution to the previous speaker's point, showing an attempt to build on the discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Are you talking like you know, like spheroid cultures and stuff? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Dr. Anna Moore asks a clarifying question, 'Are you talking like you know, like spheroid cultures and stuff?', to make Lisa's previous inquiry about '3D physiologically relevant cell culture models' more precise by offering a specific example.",
                "score": 2,
                "score_justification": "The question is precise and targeted, offering a specific example ('spheroid cultures') to clarify the type of models Lisa was asking about, which helps to make the information sought more specific and relevant."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Mainly cell cultures that can reproduce for example also the extracellular environment. So so that are really physiologically relevant but in vitro. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Lisa is providing specific details about the type of cell cultures she is referring to, clarifying her previous question by sharing relevant information about their characteristics (reproducing extracellular environment, physiologically relevant, in vitro).",
                "score": 1,
                "score_justification": "The utterance provides a clear and relevant contribution with some specific details about the cell cultures, but it is not highly elaborated or quantitative."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It feels very promising, but my personal experiment experience uh recently collaborating with somebody doing a 3D organoid model. Um we got all kinds of interesting data in addition that I went to go validate with some metabolic imaging, just nothing alike. Not even slightly. And so then we just did all the experiments over again and it told a completely different story. It turned out that, you know, sitting in millimolar glucose, which is what you have to do for the cells to survive, completely wrecked their metabolism in terms of you know, what we're looking for. So it is really easy to get to be misled by those tools. I'm not saying they're bad, but it's very easy to get misled because then you think they're real, but something that's required for the culture conditions um ruins everything. And for someone who works in neuroimmunity, like the microglia that I focus on, they know when they're in culture. They know when they're being looked at and they change their their gene transcription. So those things have been have been very frustrating for for my personal kind of work. Now, they may work in other systems, but they they've never worked for me. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker provides detailed personal experimental experience and expertise regarding the challenges and limitations of 3D organoid models, including specific issues like glucose affecting metabolism and microglia behavior in culture.",
                "score": 2,
                "score_justification": "This is accurate, detailed, and directly useful knowledge, offering concrete examples of how 3D organoids can be misleading due to specific culture conditions."
            },
            "Evaluation Practices": {
                "explanation": "The speaker evaluates the reliability and feasibility of 3D organoid models by sharing personal experimental experience that highlights their limitations and potential to mislead, providing specific reasons for these challenges.",
                "score": 2,
                "score_justification": "This is constructive, reasoned, and actionable feedback, explaining why the models can be misleading with specific examples (glucose, microglia behavior) and suggesting caution for their use."
            }
        }
    },
    {
        "utterance": "Sixian You | MIT: I think there are some positive examples for uh breast cancer. So there is a research group in Wisconsin Medicine where they uh have these organoids from patients and they culture it and then they use therapy to uh you know, treat it and then using optical imaging technologies, they are able to see if they decrease or increase. Uh I have not been following up how well that really translates to the patient's recovery because of course that takes long time to track. Uh but maybe the sensitivity. I know neurons are a beast. They are different in every different environment. So maybe some models are more robust in different um scenarios and that's the thing we could take advantage of. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker shares detailed knowledge about a research group in Wisconsin Medicine successfully using organoids from patients for breast cancer therapy and optical imaging, providing a specific positive example.",
                "score": 2,
                "score_justification": "This is accurate, detailed, and directly useful knowledge, providing a concrete example of successful application in a specific context."
            },
            "Idea Management": {
                "explanation": "The speaker introduces the idea that some organoid models are more robust in different scenarios, suggesting a strategy to leverage their utility by identifying suitable applications.",
                "score": 2,
                "score_justification": "This is a novel, elaborated, and reasoned idea that builds on the previous discussion by offering a nuanced perspective and a potential path forward for using organoids effectively."
            },
            "Evaluation Practices": {
                "explanation": "The speaker evaluates the utility of organoids by presenting a positive example and suggesting that their effectiveness is context-dependent, offering a constructive assessment of their merit.",
                "score": 2,
                "score_justification": "This provides constructive, reasoned feedback by acknowledging both the limitations and potential of organoids, offering a nuanced and actionable perspective."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: Yes, I would I would get I would agree with that. Not all organoids are the same. Uh there are some organoids that are much more robust and in vivo like such as the gut organoids are actually making real crips to feed the villi that have the the sites on them. And also the Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dylan elaborates on the idea that 'not all organoids are the same' by providing a specific example of robust gut organoids and their in vivo-like characteristics.",
                "score": 2,
                "score_justification": "He builds on Sixian's idea by providing a novel, elaborated, and reasoned example of robust organoids, moving the discussion forward."
            },
            "Knowledge Sharing": {
                "explanation": "Dylan shares specific, detailed knowledge about gut organoids, describing their robust, in vivo-like characteristics and functions.",
                "score": 2,
                "score_justification": "He provides accurate, detailed, and directly useful knowledge about a specific organoid model, enriching the team's understanding."
            },
            "Evaluation Practices": {
                "explanation": "Dylan assesses the merit of certain organoid models (gut organoids) as 'much more robust and in vivo like,' providing a positive judgment with supporting characteristics.",
                "score": 2,
                "score_justification": "He offers constructive, reasoned feedback by highlighting the specific positive attributes of certain organoids, contributing to a more nuanced understanding of their utility."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin provides a relevant fact by clarifying that his previous comments or current work also pertains to gut organoids, aligning his specific context with Dylan's example.",
                "score": 1,
                "score_justification": "It's a clear and relevant contribution that adds specific detail (gut organoids) to the discussion, but it is not highly elaborated or novel knowledge."
            },
            "Relational Climate": {
                "explanation": "Benjamin explicitly aligns his perspective with Dylan's by stating he is also referring to gut organoids, fostering shared understanding and implicit agreement.",
                "score": 1,
                "score_justification": "It's an explicit acknowledgment and alignment of perspectives, which is more than a token acknowledgment but not a strong expression of trust or enthusiasm."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: But that was metabolism. Yeah yeah yeah don't don't don't expect them to actually have the right metabolism. That's just that's a big ask. It's surviving and making similar cell types is what we're looking for here. Um that's why I think people we should we should lower our standard a little bit because to expect a something in a dish to be an in vivo environment is never going to happen. In vivo like we can probably get there. In vivo you got to go into an animal for that. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "Dylan evaluates the feasibility of expecting organoids to have 'right metabolism' and function as a full 'in vivo environment,' providing reasoning and suggesting a more realistic standard for what the team should aim for.",
                "score": 2,
                "score_justification": "The utterance provides constructive, reasoned feedback by critiquing an unrealistic expectation and proposing a more achievable standard with clear justification."
            },
            "Knowledge Sharing": {
                "explanation": "Dylan shares his expertise regarding the limitations of organoids in replicating in vivo metabolism and environment, clarifying what is realistically achievable ('surviving and making similar cell types').",
                "score": 2,
                "score_justification": "The contribution provides accurate, detailed, and directly useful knowledge about the biological capabilities and limitations of organoids, which helps to set appropriate research expectations."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): I was going to mention the same paper. Although somebody commented that the mechanism of formation was different in vivo versus in the organoid, but that the function was similar. So I do think there are limitations. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker shares specific information about a paper or comment, detailing how the mechanism of formation differs between in vivo and organoids, while function remains similar, which is relevant to the discussion on organoid models.",
                "score": 2,
                "score_justification": "The contribution provides accurate, detailed, and directly useful knowledge by highlighting a specific comparison (mechanism vs. function) between in vivo and organoid models, which is highly relevant to the ongoing scientific discussion."
            },
            "Evaluation Practices": {
                "explanation": "The speaker assesses the quality and feasibility of organoid models by stating 'I do think there are limitations,' which is a judgment based on the previously shared information about differing mechanisms.",
                "score": 2,
                "score_justification": "The utterance provides constructive, reasoned feedback by explicitly stating 'there are limitations' based on the detailed comparison of in vivo and organoid mechanisms, which helps the team understand the scope and challenges."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): But I think multi-disciplinary studies where you have people in vivo and you have organoids and then you are able to, I mean we can't study people, but you can do um patient specific therapeutics, right? So pulling cells or um or tumors out of patients to try to determine in their physiology if they can respond to these things. You kind of have to have all three because with without them you're you're running blind in some areas. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The speaker introduces and elaborates on the idea of conducting multi-disciplinary studies that integrate in vivo, organoids, and patient-specific therapeutics, providing a clear rationale for this approach.",
                "score": 2,
                "score_justification": "The utterance presents a novel and elaborated idea for a research strategy, building on previous discussions about limitations and offering a reasoned justification for its necessity."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I think some of us are you can't study people though, right? Uh Molly, you study people, but what you get is not mechanistic per se. It's like a convolution of the mechanisms. And so there's got to be some I I I wish there is some translation between the mechanisms and the convolute the complex outputs of those mechanisms. And a lot of times that's things like blood flow because that's something you can see or biomarkers that are accessible, structural changes, um liquid biopsies, things like that that give you hints as to what the mechanism might be. But um so far uh those things have not been enough to give you a a strong inference of the mechanisms that are so have been so painstakingly acquired in in model systems. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares his expertise on the limitations of studying people for mechanistic insights, explaining that human data is often a 'convolution of mechanisms' and providing examples of observable outputs like blood flow and biomarkers.",
                "score": 2,
                "score_justification": "This is accurate, detailed, and directly useful knowledge that elaborates on the challenges of translating findings from model systems to humans, moving the team's understanding forward."
            },
            "Evaluation Practices": {
                "explanation": "Benjamin evaluates the current state of human studies, stating that the data obtained is 'not mechanistic per se' and that observable outputs like blood flow and biomarkers 'have not been enough to give you a strong inference of the mechanisms.'",
                "score": 2,
                "score_justification": "This provides constructive, reasoned feedback by identifying a significant limitation in current human study approaches and implicitly highlighting a gap that needs to be addressed for better translation."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: My lab's cheating a little bit. We are not looking at small molecules, we're looking at drugs. So we're trying to repurpose FDA approved drugs because I don't really develop drugs. Uh so that's that that's how we're skirting around this issue of like you develop a small molecule that's very effective in in vitro, you go into a patient doesn't it doesn't partition correctly in the body. What the heck's no, after 10 years of work, that's annoying. So we are we are we're cheating a little bit by uh just focusing right now on repurposing FDA approved drugs that have a huge literature. So the mechanism has been delved into in vitro, in animal models and in humans as much as we can. So um there's a way around that. Now, not every problem can, you know, uh we can't pull an FDA approved drug off the shelf for every single problem. That's not going to be feasible, but there's a good handful I think we can. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dylan introduces his lab's specific approach of repurposing FDA-approved drugs as a strategy to address challenges in small molecule development, elaborating on its rationale and scope.",
                "score": 2,
                "score_justification": "The utterance presents a novel, well-reasoned strategy for drug development, detailing its advantages and acknowledging its limitations, which significantly moves the discussion forward."
            },
            "Knowledge Sharing": {
                "explanation": "Dylan shares detailed knowledge about the pitfalls of traditional small molecule development (e.g., partitioning issues, long development cycles) and the benefits of repurposing FDA-approved drugs due to their established literature and known mechanisms across models.",
                "score": 2,
                "score_justification": "The speaker provides accurate, detailed, and directly useful knowledge regarding drug development challenges and the specific benefits of their repurposing strategy, backed by existing research."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, so one of the issues is uh like I said before, is delivery and imaging that delivery. And I know that there's a maybe handful of drugs that allow for that. In fact, if I start scratching my head and trying to name one, I probably wouldn't be able to. Uh there's something on the pet side that's available, I think, but nowhere else. Do you think that this is a an important issue to be able to to see what you're delivering and where? ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares her expertise by stating that delivery and imaging are issues and that very few drugs allow for this, specifically mentioning PET as a limited exception.",
                "score": 2,
                "score_justification": "The speaker provides accurate and detailed knowledge about the scarcity of drugs for delivery and imaging, which is directly useful to the team's discussion."
            },
            "Information Seeking": {
                "explanation": "Dr. Moore explicitly asks the team if they consider the ability to image drug delivery and location an important issue.",
                "score": 2,
                "score_justification": "The question is precise, targeted, and highly relevant, seeking to establish the importance of a key technical challenge for the team."
            }
        }
    },
    {
        "utterance": "mark sellmyer: I I can I can try to uh comment on that. I mean, I think the oldest uh sort of theranostic, maybe radioactive iodine for thyroid cancer. Because there you're getting a beta emission, which is killing the actual tumor and then or the thyroid in general and then you're also getting the uh gamma emission that you can detect with the camera. And so, um in my group, um you know, we've been interested in in uh well there's quite a there's quite a lot of efforts out there that are along these lines, especially the nanoparticle community, which can label, you know, things with both therapeutics and diagnostics. My group is stuck on the concept of uh reporter genes. And because GFP's been so critical to, you know, microscopy and biomedical applications and and study, you know, if we could develop good reporter genes for in vivo and human applications, that seems critically important to look at like living drug therapies. So cells that are being regenerative medicine for your cardiac myocytes or um you know, uh car T cells are a modern example, um virally delivered vectors another another example. And so, you know, to me on that front, if you can if you can image the delivery of these types of therapeutics that have different PK because they are tend to um sense and respond to pathology, that makes it a totally different problem than just what the admin characteristics are of a of uh chemotherapy or a biologic. So I think I think the idea is is ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker shares detailed scientific knowledge by providing specific examples like radioactive iodine for thyroid cancer and the concept of reporter genes (e.g., GFP) for imaging living drug therapies, directly addressing the question about seeing what is being delivered and where.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful, offering concrete examples and expertise relevant to the discussion on drug delivery and imaging."
            },
            "Idea Management": {
                "explanation": "The speaker introduces and elaborates on the idea of using 'reporter genes' for in vivo and human applications to image 'living drug therapies,' providing examples like CAR T cells and virally delivered vectors.",
                "score": 2,
                "score_justification": "The speaker presents a novel and elaborated idea (reporter genes) that builds on the discussion, providing specific applications and examples."
            },
            "Evaluation Practices": {
                "explanation": "The speaker assesses the importance of developing good reporter genes for in vivo applications, stating that it 'seems critically important' and that imaging delivery of certain therapeutics 'makes it a totally different problem.'",
                "score": 2,
                "score_justification": "The speaker provides a constructive and reasoned evaluation of the importance of the discussed ideas, explaining why they are critical for advancing the field."
            }
        }
    },
    {
        "utterance": "mark sellmyer: is really important and how do we develop things that are able to sense drug delivery. There's also the idea um from pet because I do pet on some of my day job that you can radio label the drug itself or something that's going to um show you whether or not you're inhibiting with therapeutic doses. So example of this is the estrogen receptor um and people have made drugs like full vestrant which are estrogen receptor degrader. So that drug binds to the estrogen receptor and it's got a hydrophobic group on it that targets the whole receptor to be degraded. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "The speaker explicitly states that the idea of sensing drug delivery 'is really important,' assessing its merit in the context of the discussion.",
                "score": 1,
                "score_justification": "This is a clear positive judgment on the importance of the topic, providing a clear direction but without extensive reasoning within this specific phrase."
            },
            "Idea Management": {
                "explanation": "The speaker introduces and elaborates on a specific approach for sensing drug delivery, suggesting radio labeling drugs for PET imaging to monitor therapeutic inhibition.",
                "score": 2,
                "score_justification": "This is a novel and elaborated idea, building on the previous discussion about imaging drug delivery by proposing a concrete method with specific details."
            },
            "Knowledge Sharing": {
                "explanation": "The speaker provides a detailed, real-world example of the estrogen receptor and fulvestrant to illustrate how radio labeling can monitor drug efficacy.",
                "score": 2,
                "score_justification": "This contribution offers accurate, detailed, and directly useful knowledge, providing a concrete example to support the proposed idea."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Now if you make a estrogen receptor estradiol 4 and 18 probe, then you can use that to monitor the success of your estrogen receptor degrader in people. And so um people have have done this and it's becoming part of the standard of of drug development is try to try to develop companion diagnostic agents that are going to let you look at drug delivery and I'll stop. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker provides detailed and accurate information about using a specific probe (estrogen receptor estradiol 4 and 18 probe) to monitor the success of estrogen receptor degraders, linking it to the standard practice of developing companion diagnostic agents in drug development.",
                "score": 2,
                "score_justification": "The speaker offers accurate, detailed, and directly useful knowledge with a concrete example of a probe and its application in drug development, moving the team forward with specific expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, not not only drug delivery but also the the target engagement and dis disappearance of the target if that's the if that's the goal. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore elaborates on the previous speaker's idea of monitoring drug efficacy by adding 'target engagement and disappearance of the target' as additional aspects to consider.",
                "score": 2,
                "score_justification": "The utterance is a novel and elaborated contribution that builds on the previous speaker's idea by adding specific, relevant details to the concept of monitoring."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore provides relevant expertise by expanding the scope of monitoring beyond just drug delivery to include 'target engagement and disappearance of the target'.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by introducing specific concepts relevant to the discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um so so the word nano has been said several times. So um I I would like you guys to uh to give some thoughts about the future of nanotechnology in that regard. Um those of you who work in that area maybe want to speak a little bit. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Dr. Moore explicitly invites specific members ('those of you who work in that area') to contribute their thoughts on nanotechnology, demonstrating a targeted effort to distribute participation.",
                "score": 2,
                "score_justification": "The invitation is specific to those with expertise in nanotechnology, making it a highly effective way to solicit relevant contributions."
            },
            "Idea Management": {
                "explanation": "Dr. Moore explicitly asks for 'thoughts about the future of nanotechnology,' which is a clear request for the generation of new ideas or perspectives on the topic.",
                "score": 1,
                "score_justification": "The utterance clearly solicits ideas on a specific topic (future of nanotechnology), providing a clear direction for idea generation."
            },
            "Information Seeking": {
                "explanation": "Dr. Moore asks the group to provide 'thoughts about the future of nanotechnology,' which is a request for information and knowledge from those with expertise.",
                "score": 2,
                "score_justification": "The speaker asks a precise and targeted question about the future of nanotechnology, seeking specific knowledge from relevant experts."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, before can I comment on that? So before going to nanotechnology, I just wanted to add one more thing and it's that like the problems of the in vitro make sense from different angles when you look at it. I mean from the like the biological point of view, it makes perfect sense that they don't basically recapitulate what happens in vivo. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Morteza explicitly asks for permission to speak ('can I comment on that?') before the discussion moves to the next topic, demonstrating an attempt to manage his own contribution.",
                "score": 1,
                "score_justification": "It's a direct request to speak, which is a clear but general way of managing one's participation."
            },
            "Coordination and Decision Practices": {
                "explanation": "Morteza attempts to structure the conversation flow by stating his intention to add a point 'before going to nanotechnology,' which was the topic just introduced by Dr. Moore.",
                "score": 1,
                "score_justification": "It's a clear attempt to structure the process by interjecting a point before moving to the next agenda item."
            },
            "Idea Management": {
                "explanation": "Morteza introduces a new idea by elaborating on the problems of in vitro studies from a biological perspective, specifically their inability to recapitulate in vivo conditions.",
                "score": 1,
                "score_justification": "It's a clear idea with some detail, providing a functional contribution to the discussion."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: But like from the physical point of view, it would be another story like different organs have different stiffness. They have like different properties and all of those things needs also to be considered in the in vitro setting. Like with the advances in the 3D bioprinting and like making like um uh pattern substrates that can basically provide opportunity for cells to basically make a 3D structures rather than like the flat surface uh 2D structured, all of those can be of a great help for getting more meaningful and robust in vitro data. So I think for that purpose maybe a group of scientists that have different looks into the same problem needs to collaborate to each other to basically make a perfect in vitro like setting that can be more close to the in vivo part. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The speaker elaborates on the idea of improving in vitro models by proposing specific solutions like 3D bioprinting and patterned substrates to create 3D structures, and suggesting multidisciplinary collaboration.",
                "score": 2,
                "score_justification": "This is a novel, elaborated, and reasoned idea that builds on the previous discussion by offering concrete methods and a collaborative approach to move the team forward."
            },
            "Knowledge Sharing": {
                "explanation": "The speaker provides relevant facts about the physical properties of organs and expertise on advanced techniques like 3D bioprinting and patterned substrates for creating more robust in vitro data.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful knowledge, offering specific technical insights and a general approach to solve the problem."
            }
        }
    },
    {
        "utterance": "mark sellmyer: I'll just say on that that frame too like it's not only to just do the study if you could or study basic biology, if you can start making better 3D culture systems and start to grow organs, there's also huge biomedical applications and treatments that can come out of it. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Mark elaborates on the idea of 'better 3D culture systems' by highlighting their potential for 'huge biomedical applications and treatments,' thereby expanding on the flow of ideas beyond basic research.",
                "score": 2,
                "score_justification": "This is a novel, elaborated, and reasoned contribution that builds on the previous speaker's idea by detailing its broader implications and moving the team forward."
            },
            "Knowledge Sharing": {
                "explanation": "Mark shares relevant knowledge about the significant 'biomedical applications and treatments' that can emerge from developing better 3D culture systems and growing organs, providing directly useful information.",
                "score": 2,
                "score_justification": "The contribution provides accurate, detailed, and directly useful knowledge about the potential outcomes and significance of the discussed technology."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, exactly. These are basically the concept of the lab on a chip which basically again it's a kind of multidisciplinary thing. And for the nanotechnology, I mean, we are working in the field of nanomedicine for a couple of years and like one of the main problems that we have for delivery and also for like using them as a contrast agent is their interactions with biological systems. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Morteza explicitly acknowledges and agrees with Mark's previous point by saying \"Yeah, exactly,\" fostering a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit agreement, which is more than a token acknowledgment but not a strong acknowledgment that fosters deep trust."
            },
            "Knowledge Sharing": {
                "explanation": "Morteza shares his expertise in nanomedicine and identifies a specific problem regarding the interaction of nanoparticles with biological systems for delivery and contrast agents.",
                "score": 2,
                "score_justification": "Morteza provides accurate, detailed, and directly useful knowledge from his field of expertise, moving the team forward by highlighting a key challenge."
            },
            "Idea Management": {
                "explanation": "Morteza introduces the concept of \"lab on a chip\" and then shifts to nanotechnology, identifying a \"main problem\" within it, thereby introducing a new area of discussion or a problem for consideration.",
                "score": 1,
                "score_justification": "The utterance introduces a clear idea/problem (nanoparticle interaction) with some detail, providing a new direction for the discussion."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: So what happens is that what we makes in like laboratories are totally different from what we see like when they interact with the plasma proteins or any type of biological fluids. So what happens is that different types of biomolecules comes to the surface of nanoparticles and interact with them and basically form a corona around the surface of nanoparticles. So based on the type of the proteins, amount of the proteins, conformational changes of the proteins, basically we have totally different fate for the nanoparticles. So it can affect imaging, it can affect targeting, it can affect safety of the nanoparticles and those things basically needs to be considered in the imaging like procedures because you can imagine when you have additional layer at the surface of like nanoparticles, if you use that nanoparticles as a carrier, so what happens is that they can affect drug release. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Morteza provides detailed scientific information about how nanoparticles interact with biological fluids to form a protein corona, explaining its effects on imaging, targeting, safety, and drug release, which is relevant expertise in nanomedicine.",
                "score": 2,
                "score_justification": "The contribution is accurate, highly detailed, and directly useful knowledge, explaining a complex scientific phenomenon and its implications."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Or if you have like a fluorophore or something like that and what happens is that we may have like some unwanted interactions with those like labeling species that can affect the like the imaging capacity. So from a nanotechnology perspective, I would say we need more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Morteza shares detailed expertise from a nanotechnology perspective, explaining how fluorophores and protein corona affect imaging capacity, safety, and biological fate of nanoparticles.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about the impact of protein corona on nanoparticles' imaging capacity, safety, and biological fate, drawing from a nanotechnology perspective."
            },
            "Information Seeking": {
                "explanation": "Morteza explicitly surfaces a knowledge gap by stating, 'we need more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles.'",
                "score": 2,
                "score_justification": "The utterance precisely identifies a targeted and highly relevant knowledge gap regarding the protein corona's effect on nanoparticle safety and biological fate, moving the team towards a specific area of inquiry."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So maybe also to follow up on Morteza's point um so in my research I focus a little bit more on using nanotechnology to manipulate the light. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Lisa shares her specific research expertise, stating her focus on 'using nanotechnology to manipulate the light,' which provides relevant information about her contribution to the broader topic of nanotechnology applications.",
                "score": 2,
                "score_justification": "The utterance provides accurate and detailed knowledge about her specific research focus, which is directly useful for the team's understanding of diverse nanotechnology applications."
            },
            "Idea Management": {
                "explanation": "Lisa introduces a new idea or direction for applying nanotechnology, specifically 'to manipulate the light,' which expands the scope of the discussion beyond the previous focus on nanoparticles interacting directly in the body.",
                "score": 1,
                "score_justification": "The utterance clearly introduces a specific new idea for nanotechnology application but does not yet elaborate on it or build on previous ideas in a complex way."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So I think there is there's the whole field of you know, having nanoparticles in the body and and Morteza really nicely outlined also several of the challenges that come with that. Um and I think some of uh you know, what I think is kind of a new direction in using nanotechnology is actually um not necessarily having it interact directly in the body but having it manipulate the light with which you illuminate uh the part the biological species you want to see and actually then using light itself as a marker. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Lisa introduces a novel idea for using nanotechnology to manipulate light for imaging, presenting it as a 'new direction' in the field.",
                "score": 2,
                "score_justification": "The idea is novel, elaborated with details on how it works (manipulating light, using light as a marker), and offers a reasoned alternative to direct interaction."
            },
            "Knowledge Sharing": {
                "explanation": "Lisa shares detailed expertise about a specific application of nanotechnology, explaining how it can manipulate light for imaging and use light as a marker.",
                "score": 2,
                "score_justification": "The knowledge shared is accurate, detailed, and directly useful, describing a specific technical approach."
            },
            "Relational Climate": {
                "explanation": "Lisa explicitly acknowledges and praises Morteza's previous contribution by stating he 'really nicely outlined' the challenges.",
                "score": 2,
                "score_justification": "The utterance provides strong acknowledgment and praise for a team member's contribution, fostering a positive relational climate."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: Um and some of the things I I'd also love to get people's perspective on there is um for example also as Morteza was saying, there are new ways where you can better um model the tissue in three dimensions and actually get effects such as the extracellular matrix um and and for instance in breast cancer metastasis, the extracellular matrix actually plays a really critical role. So um I'm curious to know how do people image that today because I think using sophisticated nano optics it would be potentially possible to monitor that. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Lisa explicitly asks for others' perspectives and inquires about current methods for imaging the extracellular matrix, surfacing a gap in her knowledge or the team's shared understanding.",
                "score": 2,
                "score_justification": "The question 'how do people image that today' is precise, targeted, and highly relevant to the scientific discussion, directly moving the team forward."
            },
            "Knowledge Sharing": {
                "explanation": "Lisa provides relevant information about 3D tissue modeling, the critical role of the extracellular matrix in breast cancer metastasis, and the potential of nano optics for monitoring it.",
                "score": 2,
                "score_justification": "Lisa shares accurate, detailed, and directly useful knowledge about the biological context and potential technological solutions, enriching the team's understanding."
            },
            "Participation Dynamics": {
                "explanation": "Lisa explicitly invites contributions by stating, 'I'd also love to get people's perspective on there is,' encouraging others to share their views on the topic.",
                "score": 2,
                "score_justification": "Lisa issues a targeted invitation for perspectives on a specific, detailed scientific topic, effectively including others in the discussion."
            }
        }
    },
    {
        "utterance": "mark sellmyer: It's a great question how to image the matrix. There aren't great tools as I understand. Maybe someone else knows. I think there's some MR techniques and someone MR might be Molly can jump in and correct me but I think there are ways to look at like higher how hyaluronic acid or you know, things that are around but I I don't know too much that's um specific to ECM like imaging collagen. I mean, I guess the other other techniques that come to mind are like MR elastography that's like Yeah and and ultrasound sort of stiffness measurements. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark shares his expertise by listing specific imaging techniques (MR, MR elastography, ultrasound) relevant to the extracellular matrix, while also acknowledging limitations in current tools.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful by providing concrete examples of techniques and highlighting current gaps in knowledge."
            },
            "Relational Climate": {
                "explanation": "Mark explicitly acknowledges and praises Lisa's previous question by stating, 'It's a great question how to image the matrix.'",
                "score": 1,
                "score_justification": "This is an explicit acknowledgment and positive framing of the question, showing interest."
            },
            "Participation Dynamics": {
                "explanation": "Mark explicitly invites others, specifically mentioning Molly, to contribute their knowledge or correct his statements, fostering broader participation.",
                "score": 2,
                "score_justification": "The utterance includes a targeted invite ('Molly can jump in and correct me') tied to potential expertise, which effectively encourages specific team members to contribute."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The speaker provides a minimal acknowledgment ('Yeah.'), serving as a token response without adding substantive content or strong positive/negative sentiment.",
                "score": 0,
                "score_justification": "The utterance is a token acknowledgment, directly matching the example for a score of 0 in the codebook."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Just some extent you oh go ahead. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Mark explicitly yields the floor to another participant by saying 'go ahead,' which directly influences who gets to speak.",
                "score": 1,
                "score_justification": "The utterance is a clear, direct invitation for someone else to speak, but it is not targeted to a specific person or expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Talk to me. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "The utterance 'Talk to me' serves as a direct invitation for others to contribute to the conversation, aligning with the code's focus on who gets to speak.",
                "score": 1,
                "score_justification": "It is a clear, direct invitation for participation, but it is not targeted to a specific individual or their expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: I was just going to say that, you know, perfusion and diffusion imaging goes this it's in the same category. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Anna Moore shares her expertise by categorizing 'perfusion and diffusion imaging' as belonging to 'the same category' as the imaging techniques or substances previously discussed, providing relevant information to the conversation.",
                "score": 1,
                "score_justification": "The utterance provides a relevant contribution with some detail by classifying specific imaging techniques within the ongoing discussion about imaging capabilities."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle, ASU: Well, to some extent you can use MRscopy. Um people have picked up hyaluronic acid that way, but it's only for things that are highly um highly present there. So what is the signaling space of the ECM, what kind of cytokines have been decorating the ECM, all that stuff is kind of beyond the reach of clinical imaging without a biopsy. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker provides relevant facts and expertise about the capabilities of MRscopy (picking up hyaluronic acid) and the limitations of clinical imaging for certain substances (signaling space of ECM, cytokines) without a biopsy.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about the specific applications and limitations of MRscopy and clinical imaging."
            },
            "Evaluation Practices": {
                "explanation": "The speaker assesses the feasibility and limitations of MRscopy and clinical imaging, stating that it's 'only for things that are highly present' and that other substances are 'beyond the reach of clinical imaging without a biopsy'.",
                "score": 2,
                "score_justification": "The utterance offers a constructive and reasoned critique of the feasibility of clinical imaging, explaining its limitations for specific targets."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, lactate. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore provides 'lactate' as a specific, relevant piece of information or example related to the ongoing discussion about substances detectable via imaging or present in the extracellular matrix.",
                "score": 1,
                "score_justification": "The utterance offers a clear, relevant piece of specific knowledge ('lactate') but lacks further detail or elaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Yeah.' is a minimal response and does not explicitly demonstrate any of the defined coding behaviors, aligning with the guideline to choose 'None' for utterances with only a few words.",
                "score": 0,
                "score_justification": "No specific code applies to this minimal utterance based on the provided guidelines."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Yeah, I mean, I I think like as a big field a big wide open blue ocean of research really is the extracellular space because we know so much about cell biology, but like we don't really even know what happens to proteins very well once they get in the extracellular space, especially in the animal. So uh and it's very it's a challenging field, right? Because it's hard to um model that in in as we got this comes full circle back to the culture conditions question. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Mark introduces and elaborates on the idea that the extracellular space represents a significant and challenging 'blue ocean of research,' contributing to the generation of potential research directions.",
                "score": 2,
                "score_justification": "This is a novel and elaborated idea for a research focus, providing reasoning for its importance and challenges, which moves the team forward by identifying a key area of inquiry."
            },
            "Knowledge Sharing": {
                "explanation": "Mark shares his expertise by detailing the current state of knowledge regarding the extracellular space, highlighting the gaps in understanding protein behavior and the challenges of modeling this field.",
                "score": 2,
                "score_justification": "This contribution provides accurate, detailed, and directly useful knowledge about a complex scientific field, offering valuable context and insights for the team's discussion."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Tough. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "The utterance 'Tough' serves as a simple assessment of the difficulty or feasibility of the research area (extracellular space) that the speaker just elaborated on, aligning with the definition of Evaluation Practices.",
                "score": 0,
                "score_justification": "It is a simple, one-word judgment without further elaboration or reasoning within the utterance itself, making it a minimal contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, so I I think that uh at the end of this um at the end of the session we will need to produce some ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Dr. Anna Moore is setting a clear goal for the session, stating that the team needs to produce ideas and questions by the end, which is a key aspect of structuring the team's workflow.",
                "score": 2,
                "score_justification": "The utterance provides an explicit and clear goal for the session's output, which effectively moves the team forward by defining what needs to be achieved."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: ideas and some hard pressing questions, uh what is on the way from translating things um from models to humans. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The speaker is setting a clear goal for the session's output, stating that they need to 'produce some ideas and some hard pressing questions' related to translation from models to humans, which aligns with structuring the process and setting goals.",
                "score": 1,
                "score_justification": "The utterance provides a clear goal for the session's output, giving direction to the discussion, but it lacks specific task assignments or detailed coordination for a higher score."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um in in all those various areas, not just, you know, drug delivery but just imaging. Even translating imaging agents uh that also requires some jumping through the loops. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore elaborates on the scope of ideas and questions the team needs to generate, specifying that they should cover 'all those various areas,' including imaging, not just drug delivery.",
                "score": 2,
                "score_justification": "The utterance provides a clear and elaborated expansion of the areas for idea generation, moving the team towards a more comprehensive understanding of the task."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares relevant expertise by highlighting that translating imaging agents also involves significant challenges ('jumping through the loops'), providing context for the discussion.",
                "score": 2,
                "score_justification": "The utterance offers specific and relevant knowledge about the complexities in translating imaging agents, enriching the team's understanding of the problem space."
            }
        }
    },
    {
        "utterance": "Sixian You | MIT: Yeah, I'm really curious to know like um why why it takes 10 years, this is a very naive question. Why it takes 10 years to develop drugs and uh why it takes uh thousands of millions. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker asks precise and targeted questions about the duration and cost of drug development, directly addressing the prompt to identify 'hard pressing questions' in translation.",
                "score": 2,
                "score_justification": "The question is precise, targeted, and highly relevant to the meeting's goal of identifying challenges in translating scientific models to human applications."
            }
        }
    },
    {
        "utterance": "mark sellmyer: I guess how much clinicians get paid, it's uh, you know. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker offers a general, speculative reason ('I guess how much clinicians get paid') as a factor contributing to the high cost mentioned in the previous question, which aligns with providing a general claim of knowledge.",
                "score": 0,
                "score_justification": "The contribution is a general, vague claim and lacks specific detail or direct relevance to the drug development process itself, making it a minimal contribution."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. Sorry guys, it's a big part of it. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin acknowledges the previous comment with 'Okay,' explicitly apologizes with 'Sorry guys,' and then confirms the point with 'it's a big part of it,' collectively managing the interpersonal tone after a potentially cynical remark.",
                "score": 1,
                "score_justification": "The explicit apology 'Sorry guys' is a clear social gesture to manage the relational climate, making it more than a token acknowledgment but not a strong trust-fostering statement."
            }
        }
    },
    {
        "utterance": "mark sellmyer: As the as the clinician on the call, I can't defend anything here, but I guess the um, the the thing that strikes me is is the sheer just amount of research that needs to go in to validate safety and the amount of time that that takes and effort. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark, as a clinician, shares his expertise by explaining that the extensive research required to validate safety and the time and effort involved are key reasons for the long drug development timeline, directly addressing a previous question.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about the specific challenges and requirements in drug development, which directly answers a question raised earlier in the conversation."
            }
        }
    },
    {
        "utterance": "mark sellmyer: And then doing, you know, to get something to as an imaging probe, it's actually frankly somewhat markedly easier to get into the clinic than it is for a therapeutic where imaging probes generally are benign, right? They're not going to kill you, a radio tracer is low, MR contrast agents may be harder. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker shares specific, detailed knowledge about the comparative ease of getting imaging probes into the clinic versus therapeutics, providing reasons related to their benign nature and low risk.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful, providing concrete examples and reasoning that moves the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Somehow we've convinced people of this. Yeah, it's amazing. But yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance acknowledges Mark's previous point about imaging probes being easier to get into the clinic and expresses a mild positive sentiment ('it's amazing') about this situation, aligning with expressing acknowledgment or enthusiasm.",
                "score": 1,
                "score_justification": "The phrase 'it's amazing' provides explicit, albeit mild, positive sentiment or interest, making it more than a token acknowledgment but not a strong, trust-fostering one."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, yeah, because, you know, radio tracer, you inject them in such a small, small quantity that, you know, it's. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Anna Moore shares specific knowledge about radio tracers, explaining that they are injected in very small quantities, which directly addresses the previous discussion about their benign nature.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by explaining the reason for the benign nature of radio tracers with a specific detail about injection quantity."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh yeah, I'm talking about Gadolinium. That's just. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin provides specific and relevant information by clarifying that he was referring to Gadolinium, an MR contrast agent, which helps to focus the discussion after Dr. Moore mentioned radio tracers.",
                "score": 2,
                "score_justification": "The clarification is accurate, detailed, and directly useful, ensuring the team is discussing the correct type of imaging probe and setting up his subsequent point about the quantities used."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, Gadolinium. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah, Gadolinium' serves as a token acknowledgment, confirming understanding of the term Benjamin Bartelle just clarified.",
                "score": 0,
                "score_justification": "The utterance is a token acknowledgment, fitting the definition for a score of 0 in Relational Climate."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's some reason it's okay to put in millimolar amounts of Gadolinium into a person. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares a relevant fact about the common practice of using 'millimolar amounts of Gadolinium into a person,' which is a piece of knowledge related to the ongoing discussion about substances injected into the body.",
                "score": 1,
                "score_justification": "The contribution is a clear, relevant fact with some specific detail ('millimolar amounts') that adds to the discussion, fitting the criteria for a score of 1."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, there's a warning on the label. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Anna Moore shares a specific, relevant fact about Gadolinium, indicating that its potential risks are acknowledged, which directly contributes to the ongoing discussion about its safety.",
                "score": 2,
                "score_justification": "The utterance provides an accurate and directly useful piece of knowledge (a specific fact about the product's labeling) that is highly relevant to the team's discussion about Gadolinium's safety."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: The debate the debate rages, yeah. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The utterance shares the relevant information that an ongoing debate exists regarding the topic of Gadolinium, which was just discussed in the prior context.",
                "score": 1,
                "score_justification": "It's a clear and relevant contribution of a fact, but it lacks specific details about the debate itself."
            }
        }
    },
    {
        "utterance": "mark sellmyer: But but I think, you know, the therapeutic index for a therapy is a huge deal, right? If you you don't want to be causing toxicity and in the realm of do no harm, right? It it just takes us. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark shares his expertise by highlighting the critical importance of the 'therapeutic index' and the principle of 'do no harm' in therapy, providing relevant foundational knowledge to the ongoing discussion about patient safety.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by introducing key concepts ('therapeutic index', 'do no harm') that are highly relevant to the team's discussion on therapeutic safety."
            }
        }
    },
    {
        "utterance": "mark sellmyer: So so Sian, I I I don't know how to answer the question other than to say like as imagers, we actually are in a better position of um, getting things translated. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark shares his expertise by stating that imagers are in a better position for translating therapies, directly responding to Sian's question.",
                "score": 1,
                "score_justification": "The utterance provides a clear and relevant piece of expertise about imagers' role in translation, serving as a functional contribution."
            }
        }
    },
    {
        "utterance": "mark sellmyer: So like, you know, this was there's image guided therapies being here. People have developed fluorescent probes to thing like folate receptor or looking at um ICG for various lung cancers. So people have taken, you know, molecular imaging approaches and put those into patients without a huge, you know, long, long time to get those um, we're talking years rather than 10 years maybe to do this. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark is sharing accurate and detailed knowledge by providing concrete examples of molecular imaging approaches (fluorescent probes, ICG for lung cancers) that have been successfully translated into patients within a relatively short timeframe, supporting his earlier statement about imagers' position in translation.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge with specific examples and timelines, which moves the team's understanding forward regarding the feasibility and speed of translating imaging approaches."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, but you know, answering your question uh Sian is um, you know, just just look at the catalog from uh Charles River, you know, how much you pay for a transgenic animal. You know, it's like 250 bucks for one mouse. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore provides specific and detailed information about the cost of transgenic animals from Charles River, directly answering Sian's implied question.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by citing a specific supplier and cost for a research animal."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's a deal. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'That's a deal' expresses a positive assessment or interest in the price of transgenic animals mentioned by Dr. Anna Moore, acknowledging her shared information.",
                "score": 1,
                "score_justification": "It is a clear, positive acknowledgment of the information shared, showing interest, but not a strong or trust-fostering statement."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: We transgenic GQ animals, 400 bucks anyway. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares specific knowledge about the cost of 'transgenic GQ animals' (400 bucks), which is a relevant fact contributing to the ongoing discussion about research expenses.",
                "score": 2,
                "score_justification": "The utterance provides specific, detailed, and relevant information about the cost of a particular type of transgenic animal, directly contributing to the discussion on research expenses."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: I know. I'm with you, I'm with you. I know. And yeah, those are even higher. And then you need n equals more than three, right? To do anything, you know, anything meaningful. And then um, all the antibodies and everything, and then once you're done with the with the with the pre-clinical studies in your lab. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dr. Moore expresses agreement and solidarity with Benjamin's previous statement about high costs by saying 'I know. I'm with you, I'm with you. I know.', which fosters a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The utterance provides strong acknowledgment and agreement, fostering trust and rapport within the team."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore provides specific details about research requirements and costs, such as needing 'n equals more than three' for meaningful results and the expense of 'antibodies and everything' for pre-clinical studies.",
                "score": 2,
                "score_justification": "The utterance offers accurate, detailed, and directly useful knowledge about the practicalities and costs of scientific research, building on the prior conversation."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: You go to CROs, uh, which are contract research organizations to do tox, to do PKPD, that's all required by FDA. And I hate to show you the bills from those companies because I went through that with my uh, with the compound that we're developed. You just, you know, basically wondering, you know, how can you possibly pay for all that? So, and then, uh, the companies that, you know, they invest money in this and then they want to recover those money and then we're wondering why the drugs are so expensive because if so much money you want to recover it somehow, right? ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares detailed information about the drug development process, including the role of CROs, FDA requirements (tox, PKPD), and the high costs, drawing from her personal experience.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about the complex and expensive stages of drug development, including specific entities and regulatory steps."
            },
            "Evaluation Practices": {
                "explanation": "The speaker evaluates the financial feasibility of drug development by highlighting the immense costs associated with CROs and FDA requirements, questioning how such expenses can be covered and linking it to drug pricing.",
                "score": 2,
                "score_justification": "The utterance offers a constructive and reasoned critique of the financial challenges in drug development, explaining the underlying reasons for high costs rather than just a simple judgment."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: There's a ray of light. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The utterance signals the introduction of a new, more positive idea or approach, shifting the discussion from the previously discussed problems to potential solutions.",
                "score": 1,
                "score_justification": "It clearly indicates a shift towards a new idea, providing a functional direction for the conversation, but is not the idea itself."
            },
            "Relational Climate": {
                "explanation": "The phrase 'There's a ray of light' expresses optimism and encouragement, aiming to foster a more positive outlook after a discussion of significant challenges and costs.",
                "score": 1,
                "score_justification": "It is an explicit expression of a positive sentiment, offering encouragement and contributing to a more positive interpersonal tone."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: And that this builds on something Dylan brought up earlier is um, you were saying you're using clinically approved drugs in your your studies and that sort of gives you a shortcut, right? With the 90% of investment in new medicines is in biologic drugs. Most of these are antibody based drugs, right? And they're going after specific targets. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "Benjamin explicitly links his current point about using approved drugs to a previous contribution by Dylan, demonstrating an effort to synthesize prior discussions.",
                "score": 2,
                "score_justification": "The utterance clearly and effectively synthesizes previous contributions ('builds on something Dylan brought up earlier') to advance the current discussion."
            },
            "Idea Management": {
                "explanation": "Benjamin introduces the idea of using clinically approved drugs as a 'shortcut' to bypass some of the costly and time-consuming development steps, elaborating on a potential solution to the problems Dr. Moore highlighted.",
                "score": 2,
                "score_justification": "The utterance presents a novel and reasoned idea ('shortcut') that builds on previous discussions and offers a concrete path forward to address the challenges."
            },
            "Knowledge Sharing": {
                "explanation": "Benjamin provides relevant facts about the prevalence of biologic/antibody-based drugs and their specific targets, which supports the 'shortcut' idea and addresses the high costs and regulatory hurdles discussed earlier.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about biologic drugs, offering context and justification for the proposed solution."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Like I made an antibody against this target, antibody against that target, I've proved that it's focal enough where it doesn't cause the worst side effects. Because of the modularity of nanotechnology and biological systems, the what everyone is doing right now, at least in the synthetic biology space, is they're starting with that. like we know this biologic drug hits this target safely. And so now we're going to build a car T cell therapy around that biologic drug. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Benjamin elaborates on the previously introduced idea of using clinically approved drugs as a shortcut by explaining the modularity of nanotechnology and biological systems and how this allows building new therapies around known safe biologic drugs.",
                "score": 2,
                "score_justification": "The utterance provides a novel, elaborated, and reasoned explanation of how to leverage existing safe drugs, significantly moving the discussion forward by detailing the mechanism of the 'shortcut'."
            },
            "Knowledge Sharing": {
                "explanation": "Benjamin provides detailed and relevant expertise about current practices in synthetic biology, explaining how the modularity of systems enables the development of new therapies like CAR T cell therapy using already approved biologic drugs.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful, offering concrete examples and explaining a complex scientific approach relevant to the discussion about drug development shortcuts."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: We know that this drug goes hits T cells specifically. Great, we're building a theragnostic that's going to find the T cells and report back to us that it's done a job in it. So we have there is a way of bypassing some of that initial safety testing if you do go with these um biologics or just antibodies that are already approved. So there there's some hope there and I think the as we get better and better at this, we may start building out something like a grass list, you know, it's like generally recognized as safe list. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The speaker elaborates on the idea of using clinically approved drugs to bypass initial safety testing by providing a specific example of building a theragnostic and introduces the novel concept of a 'grass list'.",
                "score": 2,
                "score_justification": "The utterance presents a novel and elaborated idea (grass list) and builds on a previous concept with detailed reasoning, effectively moving the team's understanding forward."
            },
            "Knowledge Sharing": {
                "explanation": "The speaker provides detailed and accurate information about how approved biologics can be used to bypass initial safety testing and introduces the concept of a 'grass list' as a future development.",
                "score": 2,
                "score_justification": "The speaker shares accurate, detailed, and directly useful knowledge regarding safety testing shortcuts with approved biologics and introduces a relevant new concept ('grass list')."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Good points. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Good points' explicitly expresses acknowledgment and support for the previous speaker's contribution, fostering a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit acknowledgment and praise for the previous speaker's contribution, which is more than a token acknowledgment but less elaborated than a score of 2."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: But but I'm still wondering if, you know, wouldn't it be great if every single drug that you uh inject has somewhat some kind of an image image guided guidance image guiding properties. So you can monitor this drug. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore introduces a novel, aspirational idea about integrating image-guided properties into every drug for monitoring purposes.",
                "score": 2,
                "score_justification": "The utterance presents a novel and elaborated idea for drug development, suggesting a new approach to monitoring drugs that implicitly addresses previous discussions on safety testing."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, without sacrificing, you know, many, many animals. And avoiding those costly studies that you have to pay for because you can actually do it yourself. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Anna Moore elaborates on her previously introduced idea of image-guided drugs by explaining its benefits, specifically avoiding animal sacrifice and costly studies.",
                "score": 2,
                "score_justification": "The utterance provides a reasoned and elaborated contribution to the proposed idea, detailing specific advantages that move the discussion forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Because you can get quantitative data. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The utterance elaborates on Dr. Moore's previously introduced idea of image-guided drugs by providing a key benefit: the ability to obtain quantitative data.",
                "score": 2,
                "score_justification": "The utterance provides a specific, reasoned benefit (quantitative data) that elaborates on the proposed idea, making it more compelling and moving the discussion forward."
            },
            "Knowledge Sharing": {
                "explanation": "The utterance shares relevant knowledge by stating that image-guided drugs allow for the collection of quantitative data, which is a valuable scientific fact in this context.",
                "score": 2,
                "score_justification": "The utterance provides accurate and directly useful knowledge about a key benefit (quantitative data) of the proposed image-guided drug approach."
            }
        }
    },
    {
        "utterance": "Sixian You: So what I'm hearing is that uh, so for therapies, the major barrier is actually in biology is in in the therapies. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "The speaker explicitly attempts to summarize and synthesize Dr. Anna Moore's previous contributions by stating 'So what I'm hearing is that...' and then rephrasing the perceived major barrier in therapies.",
                "score": 1,
                "score_justification": "The speaker provides an accurate summary of a key implication from the previous contributions, focusing on the underlying barrier in therapies, which helps to integrate understanding."
            }
        }
    },
    {
        "utterance": "Sixian You: It's not image guiding technologies. But if we want to develop image guiding technologies, it will be helpful to develop something that can monitor these early changes induced by the drugs. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "Sixian You clarifies a previous point by stating that image guiding technologies are not the major barrier, which refines the team's understanding of the problem.",
                "score": 1,
                "score_justification": "The utterance accurately clarifies a specific aspect of the previous discussion, helping to refine the team's understanding."
            },
            "Idea Management": {
                "explanation": "Sixian You introduces the idea of developing technology to monitor early drug-induced changes, providing a new direction for discussion.",
                "score": 1,
                "score_justification": "The utterance presents a clear idea for developing a monitoring technology, providing a specific direction for future work."
            }
        }
    },
    {
        "utterance": "Sixian You: So either is the delivery of the. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The utterance is an incomplete attempt to elaborate on a previous idea related to monitoring or diagnostics, specifically mentioning 'delivery of the,' which falls under the scope of introducing or elaborating on ideas.",
                "score": 0,
                "score_justification": "The utterance is an incomplete thought, making it a vague and minimal contribution to the flow of ideas."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: With companion diagnostics. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The utterance provides a specific, relevant scientific term ('companion diagnostics') that clarifies and adds a concrete detail to the discussion about monitoring early changes induced by drugs, which Sixian You was discussing.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by introducing a specific, relevant concept that advances the discussion."
            }
        }
    },
    {
        "utterance": "Sixian You: Companion diagnostics. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Sixian You's utterance 'Companion diagnostics.' is a direct repetition and token acknowledgment of the term just introduced by Dr. Anna Moore, indicating that Sixian You heard and accepted the term into the discussion.",
                "score": 0,
                "score_justification": "The utterance is a brief, token acknowledgment of the previous speaker's contribution, fitting the 'Yeah.' / 'Okay.' example for a score of 0."
            }
        }
    },
    {
        "utterance": "Molly Bright: Can I weigh in on a completely different take on on I guess yeah. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Molly explicitly asks 'Can I weigh in' to request a turn to speak, indicating her desire to be included in the discussion.",
                "score": 1,
                "score_justification": "The utterance is a clear and functional request to participate, managing her own contribution to the discussion."
            },
            "Idea Management": {
                "explanation": "Molly signals her intent to introduce 'a completely different take,' indicating a new idea or perspective will be brought into the discussion.",
                "score": 1,
                "score_justification": "The utterance clearly signals the intent to introduce a new idea, contributing to the generation of ideas."
            }
        }
    },
    {
        "utterance": "Molly Bright: So I think about it from the other end and I guess I'm surrounded by very long-term treatments and also ambiguous treatments. So there are so many therapeutics and drugs that we use in humans that may or may not work for someone, we don't know how to dose it and we don't have an imaging marker of what it's doing particularly in the brain. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Molly introduces a new perspective on the discussion, shifting focus to the challenges of long-term and ambiguous treatments, and elaborates on the specific issues like unknown dosing and lack of imaging markers.",
                "score": 2,
                "score_justification": "She introduces a novel idea ('completely different take') and provides elaborated, reasoned details about the problem space, which broadens the team's understanding and moves the discussion forward."
            },
            "Knowledge Sharing": {
                "explanation": "Molly shares her expertise by detailing the real-world challenges in her domain regarding long-term and ambiguous treatments, including the absence of clear dosing and imaging markers for brain conditions.",
                "score": 2,
                "score_justification": "She provides accurate, detailed, and directly useful knowledge from her specific area of expertise, offering concrete examples of the problems faced in human treatments."
            }
        }
    },
    {
        "utterance": "Molly Bright: Um, so that's that's my domain would be the brain, that's unfortunately what I can focus on. But there are so many drugs that I think sit into this category and if you think of all of the mood disorders and anything to do with mental health, anything to do with long-term degeneration of neural function uh and and dementia. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Molly shares her domain of expertise (the brain) and provides specific examples of conditions (mood disorders, mental health, dementia) that fall under the category of long-term and ambiguous treatments she previously introduced, which is relevant and detailed knowledge.",
                "score": 2,
                "score_justification": "Molly provides accurate, detailed, and directly useful knowledge by specifying her domain and giving concrete examples of conditions relevant to her perspective."
            }
        }
    },
    {
        "utterance": "Molly Bright: We need a time scale of looking at. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Molly shares her expertise by stating a critical need for a 'time scale of looking at' treatments, which is a relevant fact from her domain for evaluating ambiguous therapeutics.",
                "score": 1,
                "score_justification": "The utterance provides a relevant piece of expertise about a necessary component for evaluation, offering clear direction but without extensive detail."
            },
            "Idea Management": {
                "explanation": "The utterance elaborates on the problem by identifying the need for a 'time scale of looking at' treatments, which serves as a clear foundational element for developing future ideas or approaches.",
                "score": 1,
                "score_justification": "The utterance provides a clear direction for an idea by highlighting a critical requirement, though it is not yet a fully elaborated proposal."
            }
        }
    },
    {
        "utterance": "Molly Bright: What a drug does and what happens in the absence of that drug in the face of huge human variability to evaluate if we're remotely close to getting after what we're after. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Molly shares detailed expertise about the complexities of evaluating drug efficacy, emphasizing the need to consider drug effects versus their absence amidst significant human variability.",
                "score": 2,
                "score_justification": "This is accurate, detailed, and directly useful knowledge that elaborates on the specific challenges in her field, moving the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Molly Bright: And that is a huge cost. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "The utterance assesses the feasibility of the previously described complex drug evaluation process by highlighting its significant cost, which serves as a judgment about the practical implications of the idea.",
                "score": 1,
                "score_justification": "It provides a clear judgment about the feasibility of the idea, with the reasoning (the complexity of the evaluation) implicitly provided by the immediate prior context."
            }
        }
    },
    {
        "utterance": "Molly Bright: Sorry, downer. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The speaker acknowledges the potentially negative impact of her previous statements on the group's morale, which is an explicit attempt to manage the interpersonal tone and relational climate.",
                "score": 1,
                "score_justification": "The utterance is an explicit acknowledgment of the negative tone of her previous contribution, showing awareness of the group's social dynamics, which is a clear contribution to managing the relational climate."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Well, I don't know. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Well, I don't know' is a short, vague phrase that does not explicitly introduce an idea, seek information, share knowledge, evaluate, manage relations, affect participation, coordinate, or integrate, aligning with the guideline for short, non-substantive utterances.",
                "score": 0,
                "score_justification": "The utterance is too vague and minimal to be scored against any specific code, thus it receives a default score of 0 for 'None'."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Is hyperpolarized a way forwards to look at function in the brain using hyperpolarized substrates with MRI? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Mark is asking a precise and targeted question about the feasibility and utility of using 'hyperpolarized substrates with MRI' to study brain function, seeking information from the team.",
                "score": 2,
                "score_justification": "The question is highly specific, targeted, and relevant to the scientific discussion, providing clear details about the method and its application."
            },
            "Idea Management": {
                "explanation": "Mark introduces a specific and detailed scientific approach, 'hyperpolarized substrates with MRI,' as a potential 'way forwards' for the project, thereby generating a new idea for consideration.",
                "score": 2,
                "score_justification": "The utterance presents a novel and elaborated idea with specific technical details and a clear application, moving the discussion towards a new potential solution."
            }
        }
    },
    {
        "utterance": "Molly Bright: Is that really going to get at the. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "The speaker questions the merit and feasibility of the previously suggested idea (hyperpolarized MRI) by asking if it will address a specific limitation of treatment efficacy.",
                "score": 1,
                "score_justification": "The utterance provides a clear judgment of an idea with an implicit reason (its ability to address a specific limitation), making it a functional contribution."
            }
        }
    },
    {
        "utterance": "Molly Bright: The limitation of this scale of treatment efficacy? Yeah. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Molly is asking a precise and targeted question about the potential limitations of the proposed method (hyperpolarized MRI) in measuring treatment efficacy, which surfaces a relevant gap in understanding its applicability.",
                "score": 2,
                "score_justification": "The question is precise, targeted, and highly relevant to the discussion, aiming to clarify a potential limitation or gap in the proposed approach."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Right. So so efficacy as measured by some um, for psychiatric disease. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Mark elaborates on the concept of 'efficacy' by specifying its context 'for psychiatric disease,' which clarifies a key component of the main idea being discussed.",
                "score": 1,
                "score_justification": "The utterance provides a clear elaboration with some detail, adding specific context to the idea of measuring efficacy in psychiatric disease."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Really hard to measure, well, harder to measure than let's say a tumor size, you know. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark shares his expertise by stating that measuring efficacy in psychiatric disease is harder than measuring tumor size, providing a relevant fact about the challenges in the field.",
                "score": 1,
                "score_justification": "The utterance provides a relevant fact about the difficulty of measuring efficacy in psychiatric disease, offering a comparison for clarity."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: almost worse that we have the wrong. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "The utterance initiates a critical assessment of the quality of metrics, implying they are 'wrong,' which is immediately elaborated with a detailed example in the subsequent utterance.",
                "score": 2,
                "score_justification": "This utterance begins a novel and elaborated critique, providing a strong, reasoned judgment about the inadequacy of current metrics, which is fully explained and exemplified in the immediate follow-up."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: metrics, right? Like Biogen Idec just spent a billion dollars on this drug that reduces Alzheimer's plaques and it worked in mice and it works in people. It reduces the Alzheimer's plaque, doesn't do anything else. You still have Alzheimer's, you just don't see the plaques as bad anymore. And so they're image guided biomar, their imaging biomarker was absolutely wrong and they were completely all in on it and they're still trying to get it to work. So so you can really get led astray with these things, yeah. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares a detailed real-world example of Biogen Idec's drug development failure due to an incorrect imaging biomarker, providing accurate and relevant knowledge to illustrate the pitfalls of using 'wrong metrics' in scientific research, building on the previous discussion about measuring efficacy.",
                "score": 2,
                "score_justification": "The utterance provides a specific, detailed, and highly relevant real-world example with concrete details (billion dollars, Alzheimer's plaques, mice/people, imaging biomarker) that directly supports and elaborates on the ongoing discussion about the challenges of measuring efficacy and the dangers of flawed metrics, making it highly useful."
            }
        }
    },
    {
        "utterance": "Molly Bright: Any anything positive to say in this direction to balance what I've done to the conversation? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Molly asks a question to seek positive information or perspectives to balance the previous negative discussion.",
                "score": 1,
                "score_justification": "The question is clear in its intent to find positive information but general in terms of the specific content sought, aligning with 'Clear but general'."
            },
            "Relational Climate": {
                "explanation": "Molly expresses a desire to shift the interpersonal tone of the conversation towards a more positive outlook, acknowledging her own contribution's potential negative impact and inviting others to contribute positively.",
                "score": 1,
                "score_justification": "The utterance is an explicit attempt to introduce a more positive tone and foster a better climate, showing self-awareness, which aligns with 'Explicit thanks/praise/interest' in fostering a positive climate."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's a world of opportunity. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin's utterance directly responds to Molly's request for something positive to 'balance' the conversation, injecting enthusiasm and optimism into the discussion.",
                "score": 2,
                "score_justification": "The statement is a strong, positive acknowledgment that directly addresses a request to foster a more optimistic and trusting climate after a cautionary example."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: understanding. So maybe on Ben's point. So basically this drug reduced the plaques in Alzheimer's and in mice it also reduced symptoms but in humans it didn't reduce symptoms. Is that correct? ",
        "annotations": {
            "Integration Practices": {
                "explanation": "Lisa summarizes Benjamin's previous point about the Alzheimer's drug's effects in mice vs. humans to confirm her understanding, which is an act of synthesizing a contribution.",
                "score": 1,
                "score_justification": "The utterance provides an accurate summary of a previous contribution, which is functional but not a comprehensive integration of multiple ideas."
            },
            "Information Seeking": {
                "explanation": "Lisa asks 'Is that correct?' to confirm the accuracy of her summary of Benjamin's point, explicitly seeking information.",
                "score": 1,
                "score_justification": "The question is clear and seeks confirmation of information, making it a functional contribution, but it is not highly precise or targeted."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. That's Aducanumab is the story there. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin provides the specific name of the drug, 'Aducanumab,' which is a relevant and accurate piece of information that confirms Lisa's summary and grounds the discussion in a concrete example.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by naming the specific drug being discussed, which is crucial for the team's understanding and further discussion."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: Okay, interesting. And does are there any ideas why or it's completely unknown? ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Lisa expresses mild interest and acknowledgment with \"Okay, interesting\" in response to Benjamin's previous explanation about the drug's effects.",
                "score": 1,
                "score_justification": "The phrase \"Okay, interesting\" is an explicit expression of interest, fitting the criteria for a score of 1."
            },
            "Information Seeking": {
                "explanation": "Lisa asks a clear question, \"And does are there any ideas why or it's completely unknown?\", to surface gaps in understanding regarding the drug's differential effects.",
                "score": 1,
                "score_justification": "The question is clear and relevant to the ongoing discussion, but it is general in nature, seeking any ideas rather than a precise, targeted piece of information."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: The the amyloid hypothesis um was you know super popular this gets back to Crystal's original point, which is uh people get hung up stuck on these mechanisms and they seem to be what you're after and in mice these amyloid plaques removal of the amyloid plaques was highly correlated with the um positive outcomes in these Alzheimer's models. We don't know if the Alzheimer's models are accurate. We don't know if Alzheimer's plaques that you see are anyway like related directly to Alzheimer's in humans. Uh human patients often have Alzheimer's plaques. They often have Alzheimer's plaques and no Alzheimer's. They sometimes have no plaques and Alzheimer's. So it was enough it was enough to go on where the animals model animal models worked. So it was worth pursuing because they were getting good data here and they could see their imaging biomarker in humans work. But it turned out or ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin provides detailed scientific information about the amyloid hypothesis, its success in mouse models, and its failures/complexities in human translation, directly addressing Lisa's 'why' question.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by explaining the scientific background and limitations of the amyloid hypothesis in response to a specific inquiry."
            },
            "Integration Practices": {
                "explanation": "Benjamin explicitly connects the current discussion about the amyloid hypothesis to 'Crystal's original point' regarding people getting 'hung up stuck on these mechanisms,' integrating a previous contribution into the current explanation.",
                "score": 2,
                "score_justification": "The utterance provides a balanced and comprehensive integration by linking the current topic to a previously discussed point, adding valuable context and depth to the explanation."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'That's crazy' expresses a strong reaction of surprise or disbelief to the complex scientific information Benjamin just shared, indicating engagement and interest in the topic.",
                "score": 2,
                "score_justification": "This is a strong acknowledgment of the information shared, fostering curiosity and engagement with the topic, which moves the discussion forward by showing active listening and processing of complex information."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I mean the case is still they're still making their case. There's their other companies based on the same amyloid hypothesis still testing the same thing. There may be some condition where it works but as yet it it does not work. So ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin provides relevant information about the ongoing status of the amyloid hypothesis in research, noting that companies are still testing it but it has not yet proven effective.",
                "score": 2,
                "score_justification": "The utterance provides accurate and detailed information about the current status of the amyloid hypothesis in research, which is directly useful for the team's understanding of the scientific landscape."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'That's crazy' expresses a strong reaction of surprise or disbelief to the information Benjamin shared about the amyloid hypothesis, indicating explicit interest in the topic, which aligns with expressing interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance is an explicit expression of strong interest or surprise, which is a clear contribution to the relational climate, but does not reach the level of fostering trust or deep curiosity."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Where did they go wrong? Did they go wrong in dish where they saw these amyloid plaques and got completely locked in on it? Did they go wrong in their animal models? Is that actually relevant to mice where the plaques are important for mice and cured them? Or is there something else going on in humans where we're just not seeing that part? Like we're getting half of it. You have it's maybe it's necessary but not sufficient. We don't know any of that stuff yet just because the human work is so slow and the one molecular marker we spent so much time on, you know these great pet tracers for Alzheimer's plaques. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker asks a series of precise, targeted questions about where the research on the amyloid hypothesis went wrong, surfacing specific gaps in understanding across different stages of scientific inquiry.",
                "score": 2,
                "score_justification": "The utterance contains multiple precise, targeted, and highly relevant questions that aim to uncover specific gaps in knowledge regarding the failures of a scientific hypothesis, moving the team towards a deeper analysis."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. Why? Oh, that's yeah, amazing. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Lisa asks 'Why?' which is a direct question seeking further explanation or clarification regarding Benjamin's assertions about the potential flaws in Alzheimer's research.",
                "score": 1,
                "score_justification": "The question 'Why?' is clear but general, seeking more information without being highly specific or targeted."
            },
            "Relational Climate": {
                "explanation": "Lisa's exclamations 'That's crazy' and 'amazing' express strong reactions and engagement with the profound implications of Benjamin's statements about Alzheimer's research.",
                "score": 2,
                "score_justification": "The strong expressions of surprise and awe foster curiosity and engagement with the significant points being discussed, moving beyond simple acknowledgment."
            }
        }
    },
    {
        "utterance": "Molly Bright: I I mean maybe one way to distill one of these issues is the time scale of knowing efficacy in humans is way too long. Um I don't know how like is there a way to work backwards? I I'm I'm not sure. Um but to to always go from small to big could mean that an entire direction is not wasted but mistargeted. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "Molly assesses the current scientific approach by stating that the \"time scale of knowing efficacy in humans is way too long\" and that going \"from small to big could mean that an entire direction is not wasted but mistargeted,\" providing a critique of the method.",
                "score": 2,
                "score_justification": "Molly offers constructive, reasoned feedback by identifying a significant problem with the current \"small to big\" research direction and explaining its potential negative outcome."
            },
            "Information Seeking": {
                "explanation": "Molly asks a direct question, \"is there a way to work backwards?\", seeking information or alternative approaches to address the identified problem.",
                "score": 1,
                "score_justification": "The question is clear and relevant to the discussion but remains general, without specific details or a highly targeted focus."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: What if the mechanism for Alzheimer's the disease progression in Alzheimer's in human beings has never actually been seen because you can't recapitulate it in a dish and you can't recapitulate it in a mouse. I don't I don't know but what if that's true then everything we're doing is wrong in Alzheimer's. And as yet there are no there are no root cause treatments for any neurodegeneration and maybe it's because we're not seeing it because we're not looking in the right place. It's possible. A world of opportunity. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Benjamin introduces a novel hypothesis about the fundamental mechanism of Alzheimer's disease progression, elaborating on why it might not have been observed and its implications for current research, which opens up new avenues for discussion.",
                "score": 2,
                "score_justification": "The utterance presents a novel and reasoned idea that challenges existing paradigms and suggests a new direction for research, thereby moving the team forward effectively."
            }
        }
    },
    {
        "utterance": "Molly Bright: We'll always have a job. Um but it's ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'We'll always have a job' is a lighthearted, somewhat resigned comment acknowledging the persistent difficulty of the scientific problems being discussed, contributing to the interpersonal tone.",
                "score": 0,
                "score_justification": "It's a brief, somewhat generic acknowledgment of the shared predicament, which is neither strongly positive nor negative, and doesn't significantly advance the relational climate."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Molly, I think your question is good about time scales, right? And the the very last question of our group 2.3 topic is can we integrate imaging across time to see the impact of a previous dosing over weeks to months or can you integrate, you know, biologic processes over time to capture something that might be a longer um longer in the making and longer in the resolution. It's tough. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Mark explicitly acknowledges and praises Molly's previous question about time scales, fostering a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit praise ('your question is good') for Molly's contribution."
            },
            "Idea Management": {
                "explanation": "Mark elaborates on Molly's general idea of 'time scales' by introducing a specific, detailed research question from their group's topic about integrating imaging and biologic processes over time.",
                "score": 2,
                "score_justification": "Mark builds on Molly's idea by providing a novel, elaborated, and reasoned research question, moving the discussion forward."
            },
            "Coordination and Decision Practices": {
                "explanation": "Mark refers to a specific, pre-defined topic from their group ('our group 2.3 topic'), indicating a structured approach to their discussion and goals.",
                "score": 1,
                "score_justification": "The utterance clearly references a specific agenda item or topic from their group, providing structure to the conversation."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: There are people doing primate research to do exactly this, right? So there was a whole session that the ORIP had about the importance of primate research, which again still isn't the same, but at least it scales up to um to us as primates. But I think that is the same it's the same thing again, right? Super expensive, very time consuming, still not exactly the same physiology and there's no guarantee that it will directly translate to humans. So so I don't know what I said. I don't think I added anything, but I just wanted to bring that up again that it we do have a way to test um it's just it's not efficient and it's super hard. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Crystal shares relevant knowledge about primate research being conducted to address the problem of recapitulating disease progression, detailing its characteristics and limitations, including a specific reference to an ORIP session.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about primate research, including specific context (ORIP session) and detailed characteristics."
            },
            "Evaluation Practices": {
                "explanation": "Crystal assesses the merit and feasibility of primate research as a solution, noting its ability to scale up to primates but also highlighting its significant drawbacks like high cost, time consumption, and physiological differences.",
                "score": 2,
                "score_justification": "The utterance offers a constructive and reasoned evaluation of primate research, detailing both its scaling benefit and significant feasibility challenges with clear explanations."
            },
            "Idea Management": {
                "explanation": "Crystal introduces and elaborates on the idea of using primate research as a potential approach to study disease progression, detailing its characteristics and limitations in response to the prior discussion about model limitations.",
                "score": 2,
                "score_justification": "The utterance introduces a relevant idea and elaborates on it with significant detail and reasoning, building on the previous discussion about finding better research models."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Millions of dollars going into marmosets for this exact reason of like maybe if mice don't tell us, maybe marmosets will. Millions being invested. Every every big neuroscience lab in America is is putting together their marmoset program in the hopes that it's going to be relevant. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares relevant facts about significant investment in marmoset research in neuroscience labs, providing context for the discussion on primate models as an alternative to mice.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about current research investments and trends in marmoset models, which is highly relevant to the team's discussion."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Right. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Right.' serves as a token acknowledgment, indicating agreement or understanding of the previous speaker's point about the investment in marmoset research.",
                "score": 0,
                "score_justification": "The utterance is a minimal, token acknowledgment, fitting the criteria for a score of 0."
            }
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The utterance is a precise and targeted question seeking information about the team's perspective on the future application of genetic reporters in human beings, directly following a discussion on the limitations of animal models.",
                "score": 2,
                "score_justification": "The question is precise, targeted, and highly relevant to the ongoing scientific discussion, moving the team towards considering a specific future direction."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin is sharing his personal belief or perspective in response to Sixian's question about the future of genetic reporters in human beings, which is a form of knowledge sharing.",
                "score": 0,
                "score_justification": "The contribution is a general claim ('I do') without any further detail or elaboration, making it a minimal contribution."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. It seemed impossible 10 years ago, but now with I mean everyone's everyone's getting into a cell based therapy and what do you how are you going to track those things? ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Mark shares relevant background knowledge by stating that genetic reporters seemed impossible 10 years ago but are now relevant due to the rise of cell-based therapy.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about the historical context and current trends in cell-based therapy."
            },
            "Information Seeking": {
                "explanation": "Mark asks a precise question about how cell-based therapies will be tracked, which is highly relevant to the discussion on genetic reporters.",
                "score": 2,
                "score_justification": "The question 'how are you going to track those things?' is precise, targeted, and highly relevant to the ongoing discussion about genetic reporters in human beings."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: But what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. So so when Crystal was talking I was like, Yeah. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dylan shares detailed knowledge about the public's lack of background in cell-based therapies and the difficulties in science communication, which is highly relevant to the discussion about genetic reporters in human beings.",
                "score": 2,
                "score_justification": "The contribution provides accurate, detailed, and directly useful knowledge about a critical societal challenge related to the scientific topic."
            },
            "Idea Management": {
                "explanation": "Dylan elaborates on the idea of genetic reporters in human beings by highlighting the significant communication and public perception challenges, thereby expanding the scope and context of the discussion.",
                "score": 2,
                "score_justification": "The utterance provides a novel and reasoned elaboration on the practical implications and challenges of the core idea, moving the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah.' serves as a minimal acknowledgment of the previous speaker's lengthy contribution about public perception and communication challenges, aligning with the definition of token acknowledgment.",
                "score": 0,
                "score_justification": "The utterance is a simple 'Yeah,' which is explicitly listed as an example of a token acknowledgment, scoring 0."
            }
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker is asking a clear question to the group, seeking their perspectives on the future of genetic reporters in human beings, which aligns with the definition of Information Seeking.",
                "score": 1,
                "score_justification": "The question is clear and relevant to the scientific discussion, but it is general in nature, asking for a broad perspective rather than a highly specific piece of information or a precise gap."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin is sharing his perspective/belief in response to Sixian's question about the future of genetic reporters, which aligns with providing relevant facts/expertise.",
                "score": 1,
                "score_justification": "The utterance is a clear and relevant contribution, directly answering the question, but it lacks further detail or elaboration."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: It's like that. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "Mark provides a simple, implicit approval of the idea's future by agreeing with the previous speaker's positive assessment regarding genetic reporters in human beings.",
                "score": 0,
                "score_justification": "The utterance is a simple approval of the idea's feasibility without any reasoning or detail, fitting the 'Simple approval/disapproval' criteria for a score of 0."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. Let's do it. Let's go. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The utterance 'Let's do it. Let's go.' elaborates on the idea of genetic reporters by expressing a strong desire and commitment to pursue it, thus moving the idea flow forward.",
                "score": 1,
                "score_justification": "It's a clear direction and endorsement of the idea, but it doesn't provide detailed elaboration of the idea itself."
            },
            "Evaluation Practices": {
                "explanation": "The phrase 'Let's do it. Let's go.' serves as a strong positive assessment of the merit and feasibility of the idea of genetic reporters.",
                "score": 1,
                "score_justification": "It's a clear positive judgment, with the enthusiasm implicitly serving as reasoning for its merit, making it more than simple approval but less than detailed constructive feedback."
            },
            "Relational Climate": {
                "explanation": "The 'Yeah' indicates agreement, and 'Let's do it. Let's go.' expresses enthusiasm and support for the idea, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance conveys explicit interest and enthusiasm, which is more than token acknowledgment but not a strong acknowledgment that fosters deep trust or curiosity."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: It's a great idea, but that requires a massive effort in science communication. And so if people won't take a vaccine to save their lives, I don't know that anybody would want to have a reporter uh inside of them. So I think we have these issues here. We are all for it. Like inject me, go for it, but um so there have to there has to be a a front of us being the scientists and the clinicians and also explaining how important and innocuous some of these things can be. They can be helpful. They can be, you know, therapeutic. They can also be um diagnostic but or theragnostics, right? That's the the term. But ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "Crystal assesses the 'great idea' by acknowledging its merit but then provides constructive criticism regarding the massive science communication effort required, supported by a relevant analogy.",
                "score": 2,
                "score_justification": "The utterance provides constructive, reasoned feedback by identifying a significant challenge and explaining its implications, moving the team forward."
            },
            "Idea Management": {
                "explanation": "Crystal introduces the idea that scientists and clinicians must lead a communication effort to explain the importance and innocuousness of the technology, elaborating on a necessary step for the initial idea's success.",
                "score": 2,
                "score_justification": "This is a novel and elaborated idea for addressing a critical challenge, building on the previous discussion and providing a clear path forward."
            },
            "Knowledge Sharing": {
                "explanation": "Crystal shares specific knowledge about the potential applications of the technology, detailing its therapeutic, diagnostic, and theragnostic capabilities.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge about the specific benefits and terminology related to the technology."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: It's like that. It's yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance explicitly acknowledges and agrees with Crystal's preceding statement about the challenges of science communication, showing understanding and support for her point.",
                "score": 1,
                "score_justification": "The utterance provides clear acknowledgment and agreement with the previous speaker's point, which is more than a token response but lacks further elaboration or strong enthusiasm."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah.' serves as a token acknowledgment of the previous speaker's contribution, indicating passive reception rather than active engagement.",
                "score": 0,
                "score_justification": "The utterance is a token acknowledgment, which is explicitly defined as a 0-score example for Relational Climate in the scoring criteria."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: I I I ran into this yesterday. I was trying to I was trying to consent a patient to image their bacteria. And the question is is is your test going to help me in any way? Yeah. And the response is it can't because it's investigational as an imaging and diagnostic it will not change your management at all. The difference for the therapy folks is they're like we don't know. We're going to see it might help you. And so that's a huge like just big difference between therapeutic intervention trials and like diagnostic like, you know, approaches. Yeah. But but what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dylan shares detailed personal experience and expertise regarding patient consent for investigational imaging, highlighting the difference in public perception between diagnostic and therapeutic trials and the general difficulty of science communication due to lack of public background and resources.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful, providing concrete examples and insights into a complex issue."
            },
            "Idea Management": {
                "explanation": "Dylan elaborates on the previously introduced idea of science communication challenges by providing a specific real-world example and detailed reasoning for why it is difficult, building on the conversation.",
                "score": 2,
                "score_justification": "The utterance provides a novel, elaborated, and reasoned contribution that significantly builds upon and deepens the discussion of communication challenges."
            },
            "Evaluation Practices": {
                "explanation": "Dylan evaluates the current state of public understanding and science communication as 'scary as hell' and 'very difficult,' providing reasoning based on patient interactions and the lack of professional science communicators.",
                "score": 2,
                "score_justification": "The evaluation is constructive and reasoned, identifying a significant problem with supporting evidence and implicitly suggesting areas for improvement."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: and that they shouldn't be, but maybe they should, right? ",
        "annotations": {
            "Idea Management": {
                "explanation": "The utterance introduces the idea that science communicators, despite their current limited presence, perhaps should be more established, contributing to the generation of ideas about how to address communication challenges.",
                "score": 1,
                "score_justification": "The utterance presents a clear idea about the potential role of science communicators, but it lacks further elaboration or concrete details, making it a functional but not highly developed contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, well, there's another approach, uh, you know, when you're talking about cell-based therapies and you need to track those cells, you don't necessarily have to have a permanent, you know, imaging reporter in your body, you could just label cells before you inject them with some kind of a label that is visible for the scanner, whether it's magnetic label, you know, I'm a nanoparticle person, so obviously, um, that's what what comes to mind, but also what's biodegradable and gets, you know, gets outside your body at some point. So that doesn't seem so scary, does it? ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore introduces a novel approach for tracking cells in cell-based therapies by suggesting pre-injection labeling with biodegradable materials, directly addressing the challenge of patient fear and the need for tracking.",
                "score": 2,
                "score_justification": "The utterance presents a novel, elaborated, and reasoned idea for cell tracking in therapies, offering a specific method (pre-injection labeling with biodegradable nanoparticles) that builds on previous concerns."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares her expertise by detailing a method for cell tracking using biodegradable magnetic labels or nanoparticles, drawing from her background as a 'nanoparticle person'.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful, providing specific technical knowledge about biodegradable nanoparticle labeling for cell tracking, grounded in her stated expertise."
            },
            "Relational Climate": {
                "explanation": "Dr. Moore attempts to alleviate a previously expressed concern about patient fear regarding cell-based therapies by framing her proposed approach as less 'scary'.",
                "score": 1,
                "score_justification": "The utterance explicitly addresses a previous concern about patient fear, attempting to reassure and foster a more positive relational climate by presenting her idea as less intimidating."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: longitudinally, I've I've had very little success with that. If you're trying to look at something over months, the chances you're going to find that nanoparticle laden T cell or that nanoparticle laden, you know, stem cell and have it persist over the months you need to follow the disease progression or therapy progression. Like we've been trying that for a long time since before I started grad school and it's just without having that genetic persistence, it hasn't worked. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares his expertise and experience regarding the lack of success with nanoparticle-laden cells for longitudinal tracking over months, providing detailed reasons for its limitations.",
                "score": 2,
                "score_justification": "The contribution is accurate, detailed, and directly useful knowledge, explaining the practical limitations of a proposed scientific method based on extensive experience."
            },
            "Evaluation Practices": {
                "explanation": "Benjamin assesses the feasibility of using biodegradable labels for long-term cell tracking, concluding it 'hasn't worked' due to lack of genetic persistence over months.",
                "score": 2,
                "score_justification": "The feedback is constructive and reasoned, providing a clear critique of the proposed method's limitations for longitudinal studies with specific scientific reasoning."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, I'm just saying like, you know, that's that's one problem with we can talk we can actually talk about that because our experience is that you could follow them for quite some time providing that cells do not divide because if they divide, then they dilute the material obviously. And and there has to be complementary methods to basically see the effect of your therapy. So you cannot kill, you know, many bunnies with one I I hate even saying that. That doesn't sound good. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares her lab's experience and expertise regarding the long-term tracking of labeled cells, providing conditions under which it is possible and mentioning the need for complementary methods.",
                "score": 2,
                "score_justification": "Dr. Moore provides accurate, detailed, and directly useful knowledge from her experience, explaining specific conditions and additional requirements for cell tracking."
            },
            "Evaluation Practices": {
                "explanation": "Dr. Moore evaluates the feasibility of long-term cell tracking by acknowledging a 'problem' raised by Benjamin but then offering reasoned conditions and additional considerations based on her experience.",
                "score": 2,
                "score_justification": "Dr. Moore provides a constructive and reasoned evaluation of the challenge, offering specific conditions and suggestions that move the understanding of the idea forward."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I've never heard this analogy, so. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin acknowledges Dr. Moore's analogy by stating he hasn't heard it before, showing mild engagement with the conversation.",
                "score": 1,
                "score_justification": "The utterance is an explicit acknowledgment of the analogy, showing mild interest, which is more than a token acknowledgment but not strong praise or curiosity."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: No. So, um, okay, so we got a, we got a warning, uh, T minus 15 minutes till the end of our. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The utterance explicitly states the remaining time in the meeting ('T minus 15 minutes till the end of our'), which serves to structure the ongoing discussion and manage the meeting's process.",
                "score": 1,
                "score_justification": "The utterance provides a clear statement about the remaining meeting time, which is a functional way to structure the process, but it lacks further detail or specific task assignments."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So basically what I was trying to say, I think you need more than one modality and more than one imaging, uh, you know, to even monitor one process. It seems like, you know, it has to be several different approaches just to make sure that your cells are injected, that they get where they have to go, uh, how much get lost on the way, whether they're doing what they're supposed to do, uh, and whether there's any improvement. So like right there it's like 1.5, like four, four different things that you need to monitor and you need four different ways to do that. I don't believe that there is like this universal contrast agent that can, you know, you can inject it and it's going to monitor everything. It doesn't exist. So anyway, so, um, like I said, we have, uh, 14 minutes now. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore elaborates on the idea that multiple modalities and imaging approaches are needed to monitor cell therapy processes, detailing what needs to be monitored and why a single agent is insufficient.",
                "score": 2,
                "score_justification": "The utterance presents a novel and elaborated idea about the necessity of multimodal approaches, providing detailed reasoning and moving the scientific discussion forward."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares her expertise by explaining the necessity of multiple modalities and imaging approaches to monitor various aspects of cell therapy, such as injection, cell migration, function, and improvement.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge regarding the complexities of monitoring cell therapy and the limitations of single agents."
            },
            "Evaluation Practices": {
                "explanation": "Dr. Moore evaluates the feasibility of a 'universal contrast agent,' concluding it 'doesn't exist,' and implicitly supports the idea of using multiple modalities as the viable approach.",
                "score": 2,
                "score_justification": "The utterance offers a constructive and reasoned critique of the 'universal contrast agent' concept, providing a clear judgment with implicit actionable direction towards multimodal approaches."
            }
        }
    },
    {
        "utterance": "Sixian You: I just put down whatever I'm hearing. So I think for the next 10 minutes, can we just uh, uh, each say or just uh, input like what is the most exciting idea you heard in this meeting or you you are summarizing and we put three major ideas in in the chat instead of uh, everything. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Sixian proposes a structured plan for the remaining 10 minutes, setting a clear goal to identify and input three major ideas into the chat, which effectively manages the meeting's workflow and moves towards closure.",
                "score": 2,
                "score_justification": "The utterance provides explicit goals and an effective coordination plan for the remaining meeting time, linked to a specific task and output."
            },
            "Participation Dynamics": {
                "explanation": "Sixian explicitly invites 'each' team member to contribute their most exciting idea, ensuring balanced participation in the proposed activity.",
                "score": 1,
                "score_justification": "It is a clear and direct invitation for all members to participate, though not specifically targeted by expertise."
            },
            "Integration Practices": {
                "explanation": "The utterance proposes an activity focused on summarizing and identifying 'three major ideas' from the meeting, which is a mechanism for combining and synthesizing contributions.",
                "score": 1,
                "score_justification": "The utterance sets up an accurate plan for summarizing and consolidating contributions, rather than performing the integration itself."
            }
        }
    },
    {
        "utterance": "Sixian You: So, so summarizing, I think um, Anna said it pretty well, so it has to be a combination of multimodal approaches uh, for these four different processes. I hear the delivery process and then the efficacy process. The other two I didn't catch it. So. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "The speaker explicitly states 'summarizing' and attempts to combine Dr. Moore's previous points about multimodal approaches for different processes, though acknowledging an incomplete understanding of all four processes.",
                "score": 1,
                "score_justification": "The summary is accurate for what was caught but incomplete, as the speaker explicitly states they 'didn't catch' all the processes."
            },
            "Information Seeking": {
                "explanation": "By stating 'The other two I didn't catch it,' the speaker implicitly surfaces a gap in their understanding of the four processes Dr. Moore mentioned, prompting further clarification.",
                "score": 1,
                "score_justification": "The statement clearly indicates a gap in understanding, but it's not phrased as a direct, specific question."
            },
            "Relational Climate": {
                "explanation": "The phrase 'Anna said it pretty well' expresses a positive acknowledgment and mild praise for Dr. Moore's previous explanation.",
                "score": 1,
                "score_justification": "The utterance includes explicit praise for Anna's explanation, contributing positively to the interpersonal tone."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, the other thing is delivery process and then, uh, you want to be able to monitor what you delivered, if it's still there, if it's still intact, if it's still functioning. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore elaborates on the 'delivery process' idea by specifying the critical aspects that need to be monitored, such as the presence, intactness, and functioning of the delivered material.",
                "score": 1,
                "score_justification": "The utterance provides clear detail, elaborating on a previously mentioned idea without introducing a novel concept or building extensively on others' ideas in a complex way."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares her scientific expertise by detailing the specific criteria for monitoring the delivery process, including whether the delivered material is still there, intact, and functioning, in response to a request for clarification.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by specifying concrete monitoring requirements relevant to the scientific discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: You know, like say the cells, right? The cell therapy, uh, are they still functioning? Are they still like for example with islet transplantation, you put islets in the human body and 60% of them dead two weeks after transplantation. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dr. Moore elaborates on the idea of monitoring delivered cells' functionality by providing a detailed example of islet transplantation and cell death, making the concept more concrete.",
                "score": 2,
                "score_justification": "The utterance provides a novel and elaborated example that significantly clarifies and moves forward the understanding of the monitoring functionality idea."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares specific, detailed knowledge about cell therapy and islet transplantation, including the statistic of 60% cell death, which is highly relevant to the discussion of monitoring efficacy.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge with a concrete example and statistic, enhancing the team's understanding of the problem."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: And you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely. And each, uh, islet batch comes from a donor who's obviously deceased. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Dr. Moore explicitly highlights significant gaps in knowledge regarding the fate and function of transplanted cells, stating 'you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely.'",
                "score": 2,
                "score_justification": "The utterance precisely identifies multiple critical information gaps ('where they went,' 'what they're doing,' 'if they're producing insulin'), making it a highly relevant and targeted inquiry into the problem."
            },
            "Knowledge Sharing": {
                "explanation": "Dr. Moore shares relevant expertise by detailing the challenges of islet transplantation, including the lack of knowledge about cell function and the source of the islet batches from deceased donors.",
                "score": 2,
                "score_justification": "The utterance provides concrete details about the problem (e.g., 'blind completely,' 'islet batch comes from a donor who's obviously deceased'), which are accurate and directly useful facts/expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So it's just an example. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "The utterance clarifies that the preceding detailed explanation about islet transplantation was an example, helping the team understand how to integrate that specific information into the broader discussion.",
                "score": 1,
                "score_justification": "The utterance provides an accurate clarification of the role of her previous contribution, helping to frame it within the discussion, but it is not a comprehensive integration."
            }
        }
    },
    {
        "utterance": "Sixian You: Mhm. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Mhm' serves as a token acknowledgment, indicating that the speaker is listening to the previous speaker without providing substantial feedback or engagement.",
                "score": 0,
                "score_justification": "The utterance is a minimal, token acknowledgment, fitting the description for a score of 0 in Relational Climate."
            }
        }
    },
    {
        "utterance": "Sixian You: One idea that I think is super exciting is this idea of long-term genetic reporters. It is high risk, it is very controversial, but um, but for auto imaging they provide really good contrast and they they're they're almost forever if they don't get injected, ejected out of the body. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The speaker introduces a novel idea, 'long-term genetic reporters,' and elaborates on its characteristics, including its risks and benefits for auto imaging.",
                "score": 2,
                "score_justification": "The utterance introduces a novel idea and provides detailed elaboration on its characteristics and potential benefits, moving the discussion forward."
            },
            "Evaluation Practices": {
                "explanation": "The speaker evaluates the proposed idea by presenting both its challenges ('high risk,' 'very controversial') and its advantages ('good contrast,' 'almost forever') for auto imaging.",
                "score": 2,
                "score_justification": "The utterance provides a constructive and reasoned evaluation of the idea, detailing both its risks and its benefits, which is actionable feedback."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Genetic reporter, I'm all for it. I have one. Anyone wants it. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin expresses strong enthusiasm and support for Sixian's idea of genetic reporters by stating 'I'm all for it,' which fosters a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The utterance provides strong acknowledgment and enthusiasm for the idea, which fosters trust and a positive climate."
            },
            "Knowledge Sharing": {
                "explanation": "Benjamin shares the relevant fact that he possesses a genetic reporter and offers it to the team ('I have one. Anyone wants it.'), providing directly useful knowledge and a resource.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by offering a specific resource relevant to the discussed idea."
            },
            "Idea Management": {
                "explanation": "Benjamin supports Sixian's idea and elaborates on its potential by offering a concrete resource ('I have one. Anyone wants it.') that could be used to pursue the genetic reporter concept.",
                "score": 2,
                "score_justification": "The utterance builds on the previously introduced idea by offering a novel and concrete resource, thereby elaborating on the idea and moving it forward."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: We bring up theranostic a lot. We've said that a number of times. Um, and it's the great thing to say, um, but what exactly is a theranostic when we go through it and it neither needs to be um, some nanotechnology, some macromolecular complex that is detectable and sensitive to a specific readout or it needs to be uh an engineered cell that uh is detectable and then can change its its signal or shape. You need to have that level of complexity to have a theranostic. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker explicitly asks 'but what exactly is a theranostic when we go through it,' indicating a need to clarify or define a concept that has been frequently discussed.",
                "score": 2,
                "score_justification": "The question is precise and targeted, seeking a clear definition of a term that is highly relevant to the team's ongoing discussions."
            },
            "Knowledge Sharing": {
                "explanation": "The speaker provides a detailed definition of a theranostic, outlining specific characteristics and examples of what it needs to be (e.g., nanotechnology, engineered cell, detectable, sensitive to readout).",
                "score": 2,
                "score_justification": "The contribution offers accurate, detailed, and directly useful knowledge by elaborating on the definition and necessary complexity of a theranostic."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh, it has to be for the right mechanism. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "The speaker is setting a critical condition ('it has to be for the right mechanism') for the concept of a theranostic, which serves as a judgment on what makes a theranostic valid or effective.",
                "score": 1,
                "score_justification": "The utterance provides a clear judgment with implicit reasoning by stating a necessary condition for a theranostic, adding detail to the concept."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think that was the thing. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker confirms the importance of the previously stated detail ('it has to be for the right mechanism') regarding the definition of a theranostic, reinforcing a piece of shared knowledge.",
                "score": 1,
                "score_justification": "The utterance is a clear, relevant confirmation of a specific detail, making it functional but not elaborative."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Okay.' serves as a minimal acknowledgment, indicating the speaker has processed the preceding information or is ready for the next contribution.",
                "score": 0,
                "score_justification": "This is a token acknowledgment, fitting the definition for a score of 0 in Relational Climate."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: But we haven't really talked too much about toxicity and the ability to actually detect uh tissue that is dying either through necrosis or apoptosis or some either programmed or not programmed cell death. It's something that is would be quite useful I think if you're putting drugs into people and then you want to drugs where they go where they go, but if they're causing damage along the way or when they get concentrated at the side of of where they're supposed to be at, it's hard to tell. Um, and I know in in in neurobiology if you actually saw the neurons dying that wouldn't be bad. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dylan introduces a new idea for discussion, focusing on the importance of detecting toxicity and dying tissue, and elaborates on its utility in drug administration.",
                "score": 2,
                "score_justification": "This is a novel and elaborated idea that proposes a new, relevant direction for the team's work, moving the discussion forward effectively."
            },
            "Knowledge Sharing": {
                "explanation": "Dylan shares relevant expertise by explaining the significance of detecting tissue toxicity and cell death in the context of drug development and neurobiology.",
                "score": 2,
                "score_justification": "Dylan provides accurate, detailed, and directly useful knowledge by explaining the practical importance and context of the proposed idea."
            },
            "Evaluation Practices": {
                "explanation": "Dylan assesses the merit of the proposed idea by stating that detecting tissue toxicity and cell death 'would be quite useful' for monitoring drug effects.",
                "score": 1,
                "score_justification": "Dylan provides a clear judgment of the idea's utility with some reasoning, but it's a general positive assessment rather than a detailed constructive critique."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: So you're saying cell death as a target for our imaging and theranostic then. Like understanding that. Yeah, so if you had a read out to to to actually monitor uh the the target tissues uh actual death or not because sometimes in the case of cancer you want to kill these things, but sometimes you don't want to kill it. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Benjamin seeks clarification by rephrasing Dylan's idea to confirm his understanding of cell death as a target for imaging and theranostics.",
                "score": 1,
                "score_justification": "Benjamin clearly seeks confirmation of Dylan's idea by rephrasing it, providing a functional but not highly precise or targeted inquiry."
            },
            "Idea Management": {
                "explanation": "Benjamin elaborates on Dylan's idea of cell death as a target by adding details about monitoring tissue death and the varying desirability of cell death in different contexts like cancer.",
                "score": 2,
                "score_justification": "Benjamin elaborates on Dylan's idea by adding reasoned context about the varying desirability of cell death, which moves the idea forward with more detail and nuance."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: So so it could be both targeted and just a general read out of toxicity because sometimes you don't want your cells to die. Um, as a matter of fact, I don't want more of my cells to die in general. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Dylan elaborates on the idea of monitoring cell death by clarifying its dual application as both a targeted and general toxicity readout, building on his previous contribution.",
                "score": 2,
                "score_justification": "The utterance elaborates on a previously introduced idea by providing a reasoned distinction between targeted and general toxicity readouts, making it a novel and elaborated contribution."
            },
            "Knowledge Sharing": {
                "explanation": "Dylan shares knowledge about the dual nature of cell death monitoring, explaining that it can be targeted (e.g., cancer) or a general toxicity readout (where cell death is undesirable).",
                "score": 2,
                "score_justification": "The utterance provides accurate and detailed knowledge about the dual application of cell death monitoring, which is directly useful for the project's scope."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, a long time ago there was an an an ex in five probes developed, I would say 20 years ago to monitor tumor response to therapy. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Dr. Moore provides relevant historical information about 'ex in five probes' developed 20 years ago to monitor tumor response to therapy, which is directly related to the ongoing discussion about detecting cell death and toxicity.",
                "score": 2,
                "score_justification": "The contribution offers accurate, detailed, and directly useful knowledge by providing a specific historical example of probes used for a related purpose, enriching the team's understanding and context."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: just like, oh, everything's ferroptosis, right? ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance uses a sarcastic tone (\"oh, everything's ferroptosis, right?\") to express cynicism about the perceived overemphasis on ferroptosis in the scientific community, which can be dismissive.",
                "score": -1,
                "score_justification": "The sarcastic tone is dismissive of a scientific trend, potentially undermining the collaborative atmosphere."
            },
            "Evaluation Practices": {
                "explanation": "Benjamin makes a dismissive judgment about the idea that ferroptosis is the answer to everything, implicitly critiquing the overemphasis on this specific cell death mechanism.",
                "score": -1,
                "score_justification": "The utterance offers a dismissive judgment of a scientific trend without providing constructive reasoning or alternative ideas."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: Um, but uh, but so it's it's probably impossible to have one particular marker to pull off, you know, actually knowing what kind of of cell death, but it would be nice to know if cells are alive or not inside of of a biotic. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "Dylan evaluates the feasibility of using a single marker to identify specific cell death types, stating it's 'probably impossible.'",
                "score": 1,
                "score_justification": "The utterance provides a clear judgment on the feasibility of a single marker, offering a reason for its difficulty."
            },
            "Idea Management": {
                "explanation": "Dylan introduces the idea/goal of wanting to know if cells are alive or not, shifting the focus from specific cell death types to a more general state.",
                "score": 1,
                "score_justification": "The utterance clearly introduces a new, more general idea for investigation, providing a functional direction for the team."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. So, um, so let's see. So, um, Sision, do you do you feel comfortable talking about those things? ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Dr. Moore directly invites Sixian to contribute by asking if they feel comfortable discussing the previous complex topics, which is a targeted invitation considering Sixian's potential expertise or comfort level.",
                "score": 2,
                "score_justification": "The utterance is a direct and targeted invitation to a specific team member, acknowledging the complexity of the topic and inviting their input, which effectively promotes inclusive participation."
            },
            "Relational Climate": {
                "explanation": "Dr. Moore expresses support and acknowledgment by asking Sixian about their comfort level in discussing the complex topics, which fosters a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The question demonstrates empathy and consideration for Sixian's comfort, creating a supportive environment that fosters trust and psychological safety within the team."
            }
        }
    },
    {
        "utterance": "Sixian You: Actually, uh, yeah, I I think I can only catch understand like 50% of these conversations. I think my biology is probably high school level, so. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Sixian is providing accurate and detailed information about their level of biological understanding, which is relevant expertise for the ongoing scientific discussion and directly responds to a question about their comfort in discussing the topic.",
                "score": 2,
                "score_justification": "The utterance provides accurate and detailed information about Sixian's expertise level, which is directly useful for the team to understand their capacity to contribute to the current discussion."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's pretty good though. 50%'s pretty good. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin is offering explicit praise and encouragement to Sixian by validating their 50% understanding as 'pretty good,' which fosters a supportive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit praise and encouragement to Sixian, contributing to a positive relational climate."
            }
        }
    },
    {
        "utterance": "Sixian You: So if anybody wants to take over, I'm totally comfortable because I think the best thing is that we present the best ideas in the room. Um, yeah. ",
        "annotations": {
            "Participation Dynamics": {
                "explanation": "Sixian offers to cede their speaking turn to others, explicitly balancing contributions by inviting others to take over for the benefit of presenting the best ideas.",
                "score": 2,
                "score_justification": "Sixian's offer is reasoned ('best ideas in the room') and aims to make the team more effective by ensuring the most knowledgeable person speaks, moving the team forward."
            },
            "Relational Climate": {
                "explanation": "Sixian expresses a supportive and collaborative attitude by prioritizing the team's goal of presenting the best ideas, fostering trust and a positive interpersonal tone.",
                "score": 2,
                "score_justification": "Sixian's statement fosters trust by demonstrating a commitment to the team's success and a willingness to be flexible for the collective good."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Nah, you got this. Come on. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Benjamin expresses strong support and encouragement to Sixian, who had just offered to step down due to a perceived lack of understanding, by saying 'Nah, you got this. Come on.'",
                "score": 2,
                "score_justification": "The utterance provides strong acknowledgment and encouragement, actively fostering trust and confidence in Sixian to continue leading the discussion."
            }
        }
    },
    {
        "utterance": "Sixian You: Okay. So. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Okay. So.' is a minimal, vague response that does not explicitly demonstrate any of the behaviors defined in the codebook, such as introducing ideas, seeking information, sharing knowledge, evaluating, or coordinating.",
                "score": 0,
                "score_justification": "The utterance is too vague and minimal to be scored against any specific code, aligning with the guideline for short, non-substantive utterances."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Do we we have our our barriers, our targets, our agents, our approaches. This is all getting really well organized, so I. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "Benjamin lists specific categories (barriers, targets, agents, approaches) to summarize or confirm the components of their ongoing work, aligning with synthesizing contributions.",
                "score": 1,
                "score_justification": "The utterance provides an accurate summary of some specific contributions by listing key components."
            },
            "Evaluation Practices": {
                "explanation": "Benjamin explicitly assesses the quality of the team's work, stating that it is 'getting really well organized,' which is a positive judgment of their ideas and progress.",
                "score": 1,
                "score_justification": "The utterance offers a clear positive judgment with implicit reasoning about the organization of their work."
            },
            "Relational Climate": {
                "explanation": "Benjamin expresses enthusiasm and support for the team's progress by stating that their work is 'getting really well organized,' which fosters a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit praise for the team's collective effort, contributing to a positive relational climate."
            }
        }
    },
    {
        "utterance": "Sixian You: Oh. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Oh' serves as a minimal, token acknowledgment in response to the previous speaker's positive comments about the organization of their work.",
                "score": 0,
                "score_justification": "The utterance is a token acknowledgment, fitting the definition for a score of 0 in the Relational Climate category."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think it's really shaping up. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "This utterance expresses enthusiasm and support for the progress and organization of the team's work, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "It's an explicit expression of enthusiasm and praise for the work's progress, which is more than token acknowledgment."
            },
            "Evaluation Practices": {
                "explanation": "This utterance provides a positive assessment of the quality and progress of the ideas and their organization, building on the previous statement about things being 'well organized'.",
                "score": 1,
                "score_justification": "It's a clear positive judgment about the state of the work, with implicit reasoning from the previous utterance about the organization of elements."
            }
        }
    },
    {
        "utterance": "Sixian You: Okay. So, uh, I guess to start, we can kind of present to the room like what are the barriers? Uh, and the barriers of course, disparity between the models and uh, the lack of understanding, uh, and the lack of tools to um, to validate toxicity and efficacy uh, in the short timeline. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Sixian proposes a structure for the discussion by suggesting they 'present to the room like what are the barriers,' which sets an agenda item for the meeting.",
                "score": 1,
                "score_justification": "The utterance provides a clear structuring of the meeting by proposing to present the barriers, which is a clear agenda item."
            },
            "Knowledge Sharing": {
                "explanation": "Sixian shares specific, relevant knowledge about the project's challenges, detailing 'disparity between the models,' 'lack of understanding,' and 'lack of tools to validate toxicity and efficacy in the short timeline.'",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by explicitly listing specific barriers relevant to the project."
            }
        }
    },
    {
        "utterance": "Sixian You: And then to address that, we could first we could um, focus more efforts on different targets, uh, list at this and then contrast agency is another effort and then uh, in the end it will be a combination multi model approaches of all this. ",
        "annotations": {
            "Idea Management": {
                "explanation": "The speaker introduces and elaborates on potential solutions to the previously mentioned barriers, proposing 'focus more efforts on different targets,' 'contrast agency,' and 'combination multi model approaches,' which aligns with the definition of Idea Management.",
                "score": 1,
                "score_justification": "The utterance presents clear ideas for addressing the barriers, providing a functional direction, but these ideas are not yet fully elaborated or highly detailed."
            }
        }
    },
    {
        "utterance": "Sixian You: Where does imaging come in? The multimodal approaches in the contrast agents? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "The speaker asks a precise and targeted question about how 'imaging' fits into the previously discussed 'multimodal approaches' and 'contrast agents,' seeking to clarify its role in the proposed solutions.",
                "score": 2,
                "score_justification": "The question is precise, targeted, and highly relevant to the ongoing discussion, moving the team forward by clarifying the integration of a key component."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. I mean that's what we mean by multimodal, multimodal imaging. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin clarifies the meaning of 'multimodal' in their context by specifying it refers to 'multimodal imaging,' directly addressing Sixian's previous question about where imaging fits in.",
                "score": 2,
                "score_justification": "The utterance provides accurate, detailed, and directly useful knowledge by defining a key term, which helps resolve ambiguity and moves the discussion forward."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: Well, and also in the technological development, right, to be able to actually see the efficacy of these things live in an organism. Someday. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Crystal elaborates on the ongoing discussion by introducing 'technological development' as a key area, specifying its purpose to 'see the efficacy of these things live in an organism.'",
                "score": 2,
                "score_justification": "This is a novel and elaborated idea that builds on the previous discussion by adding a new, relevant dimension and a clear, reasoned purpose, moving the team forward."
            },
            "Knowledge Sharing": {
                "explanation": "Crystal provides relevant information by connecting the previous discussion of multimodal approaches to the broader concept of 'technological development' and its goal of observing efficacy in vivo.",
                "score": 2,
                "score_justification": "This is accurate, detailed, and directly useful knowledge that clarifies the scope and purpose of the technological development aspect within the project."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Is is is multimodal approaches a subset of technological development then? ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Benjamin asks a precise and targeted question to clarify the conceptual relationship between 'multimodal approaches' and 'technological development,' which is highly relevant to the ongoing discussion.",
                "score": 2,
                "score_justification": "The question is precise and targeted, aiming to clarify a key conceptual relationship that is highly relevant to the discussion, thus moving the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: It is. Yes. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Crystal provides a direct and accurate confirmation ('It is. Yes.') to Benjamin's question about whether multimodal approaches are a subset of technological development, thereby sharing relevant information.",
                "score": 1,
                "score_justification": "The utterance is a clear and relevant contribution, providing a direct answer to a question, but it lacks further detail or elaboration to be a 2."
            }
        }
    },
    {
        "utterance": "Sixian You: Yeah. Uh-huh. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah. Uh-huh.' serves as a simple acknowledgment or agreement with the previous speaker's statement, aligning with the definition of Relational Climate.",
                "score": 0,
                "score_justification": "The utterance is a minimal, token acknowledgment, directly matching the description for a score of 0 in the Relational Climate category."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I guess all this stuff then. These things are all like uh development of 3D culture, visualization of delivery. That's all tech development that we're all tracking. ",
        "annotations": {
            "Integration Practices": {
                "explanation": "Benjamin synthesizes Crystal's confirmation that multimodal approaches are tech development with his own examples (3D culture, visualization) to form a comprehensive understanding of what constitutes 'tech development'.",
                "score": 2,
                "score_justification": "The utterance provides a balanced and comprehensive integration of previous input and new examples, solidifying the team's shared understanding of the category."
            },
            "Idea Management": {
                "explanation": "Benjamin elaborates on the idea of 'technological development' by listing specific examples that fall under this category, building on the previous clarification.",
                "score": 2,
                "score_justification": "The utterance provides a clear, elaborated, and reasoned definition of 'tech development' with specific examples, moving the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Sixian You: So, I can delete this and uh, put multimodal approaches here. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The utterance proposes a specific modification to a shared document or list by deleting one item and adding 'multimodal approaches,' which is a clear action to structure the team's content or process.",
                "score": 1,
                "score_justification": "The utterance provides a clear and specific suggestion for organizing the content, making it a functional contribution to coordination."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah.' serves as a token acknowledgment of Sixian You's previous statement, indicating minimal engagement with the interpersonal tone.",
                "score": 0,
                "score_justification": "The utterance is a token acknowledgment, providing a barely functional contribution to the relational climate."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: I think the 3D cell culture stuff is also part of technological development, bioprinting, etc. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Crystal contributes to structuring the project's content by explicitly stating that '3D cell culture stuff' and 'bioprinting' are part of 'technological development,' helping to organize the team's understanding of topics.",
                "score": 1,
                "score_justification": "The utterance provides a clear contribution to structuring the project's scope by categorizing specific items, but it doesn't involve setting explicit goals or detailed task assignments."
            },
            "Idea Management": {
                "explanation": "Crystal elaborates on the idea of 'technological development' by providing specific examples like '3D cell culture stuff' and 'bioprinting,' thereby adding detail to the concept.",
                "score": 1,
                "score_justification": "The utterance presents a clear elaboration of an existing idea with some specific details, moving beyond a vague statement."
            }
        }
    },
    {
        "utterance": "Sixian You: Uh, that is also, okay. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Uh, that is also, okay' serves as a minimal acknowledgment of Crystal's previous statement, indicating acceptance or understanding without further elaboration, which aligns with the definition of Relational Climate.",
                "score": 0,
                "score_justification": "The utterance is a token acknowledgment ('Okay') of another's contribution, providing minimal social support without further detail or enthusiasm, fitting the criteria for a score of 0."
            }
        }
    },
    {
        "utterance": "Sixian You: I think we talked about this before. Yeah, particle, nanoparticle is already in the contrast agents. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "The speaker shares a relevant fact that nanoparticles are already used in contrast agents, drawing on previously discussed or established knowledge.",
                "score": 1,
                "score_justification": "The contribution is a clear and relevant fact, but it lacks the specific, detailed, and directly useful knowledge that would warrant a score of 2."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: You can make the the font smaller too if it doesn't fit. That's uh that's the easy one. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "The utterance offers a practical suggestion about adjusting font size to manage the display of information, which contributes to structuring the process of their collaborative work.",
                "score": 1,
                "score_justification": "It's a clear, functional suggestion for managing the presentation of information, contributing to the workflow without being highly elaborate or setting major goals."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: I also want to add the concept of like live contrast agents, like what happens with magnetotactic bacteria because like the dilution of the like the contrast agent is a big problem in the like the cell proliferation. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Morteza introduces the new concept of 'live contrast agents' and 'magnetotactic bacteria' into the discussion, which is a new idea for consideration.",
                "score": 1,
                "score_justification": "The utterance presents a clear idea with some detail (specific type of agent and a problem it addresses), providing a clear direction for discussion."
            },
            "Knowledge Sharing": {
                "explanation": "Morteza provides relevant information about 'live contrast agents' and 'magnetotactic bacteria' and explains their relevance by highlighting the problem of contrast agent dilution in cell proliferation.",
                "score": 1,
                "score_justification": "The contribution is relevant and provides some specific details about a concept and its application, moving beyond a general claim."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. ",
        "annotations": {
            "Knowledge Sharing": {
                "explanation": "Benjamin shares his expertise by clarifying the definition of 'live contrast agents' by linking it to 'genetic reporters'.",
                "score": 2,
                "score_justification": "Benjamin provides a precise definition by equating 'live contrast agents' with 'genetic reporters,' which is highly relevant and useful for the discussion."
            },
            "Idea Management": {
                "explanation": "Benjamin elaborates on Morteza's idea of 'live contrast agents' by clarifying its definition and connecting it to 'genetic reporters'.",
                "score": 2,
                "score_justification": "Benjamin's clarification of 'live contrast agents' as 'inherent in genetic reporters' is a reasoned elaboration that helps define and advance the understanding of Morteza's idea."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: So the live contrast like there are papers coming out showing basically that magnetotactic bacteria can be used for like even increasing the like uh imaging uh sensitivity and capacity at the side of like for cell therapy applications, they they at least they showed promising results. So maybe adding. ",
        "annotations": {
            "Idea Management": {
                "explanation": "Morteza elaborates on his idea of using magnetotactic bacteria as live contrast agents by providing evidence from scientific papers about their potential to increase imaging sensitivity for cell therapy applications.",
                "score": 2,
                "score_justification": "The utterance provides a novel and elaborated idea, building on his previous statement, with reasoned support from scientific literature."
            },
            "Knowledge Sharing": {
                "explanation": "Morteza shares specific knowledge from scientific literature, stating that papers show magnetotactic bacteria can increase imaging sensitivity and capacity for cell therapy applications.",
                "score": 2,
                "score_justification": "The contribution provides accurate, detailed, and directly useful knowledge by referencing research findings and their practical applications."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. It's a a live reporter. I mean, I I agree. I agree with you completely. ",
        "annotations": {
            "Information Seeking": {
                "explanation": "Benjamin asks a precise question to confirm the understanding of 'live contrast agents' in relation to 'genetic reporters,' seeking to clarify a concept.",
                "score": 2,
                "score_justification": "The question is precise and targeted, seeking to clarify a specific concept, which moves the discussion forward by ensuring shared understanding."
            },
            "Knowledge Sharing": {
                "explanation": "Benjamin provides a clear definition of 'live contrast agent' by equating it to a 'live reporter,' sharing relevant expertise to clarify a concept.",
                "score": 2,
                "score_justification": "The contribution is accurate and detailed, clarifying a technical term that is directly useful for the team's understanding."
            },
            "Relational Climate": {
                "explanation": "Benjamin explicitly expresses complete agreement with Morteza, fostering a positive interpersonal tone and supporting the previous speaker.",
                "score": 2,
                "score_justification": "The strong and explicit agreement fosters a positive relational climate and validates the previous speaker's contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, we have uh probably one or a little bit over one minute left. So I just wanted to say that uh I I think it was fun. I think you know, I think we discussed a lot of different questions because the topic is so broad. And um if you guys you know, if you guys want to talk more about it, you know, my email is there. Uh you can email me or you can email each other. Please, um and uh hopefully we'll get this going and uh I'm looking forward to forming proposals from you guys. Just think what what you want to do. Um, you have complimentary expertise. Um, so we have a clinical person here. That's unique. So grab his expertise before it's too late. ",
        "annotations": {
            "Coordination and Decision Practices": {
                "explanation": "Dr. Moore structures the end of the meeting by noting the remaining time, sets a future goal of forming proposals, and provides a clear mechanism for continued collaboration (email).",
                "score": 2,
                "score_justification": "The utterance explicitly sets clear goals ('forming proposals'), effectively coordinates by providing a communication channel, and structures the meeting's closure, moving the team forward."
            },
            "Relational Climate": {
                "explanation": "Dr. Moore expresses positive sentiment about the meeting ('it was fun', 'discussed a lot') and encourages future engagement in a supportive and enthusiastic tone.",
                "score": 2,
                "score_justification": "The strong positive acknowledgment ('it was fun') and encouragement for future collaboration fosters trust and enthusiasm among team members."
            },
            "Participation Dynamics": {
                "explanation": "Dr. Moore encourages continued participation by inviting team members to email each other and specifically highlights the unique 'clinical person' and encourages others to leverage his expertise.",
                "score": 2,
                "score_justification": "The utterance provides a targeted invite for continued interaction and specifically highlights and encourages leveraging a team member's unique expertise, making the team more effective."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: Thanks everyone. I feel like I learned a lot as a physics engineering person and I really appreciated the discussion. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance expresses explicit thanks and strong appreciation for the discussion, highlighting a significant learning experience, which fosters a positive interpersonal tone and trust among team members.",
                "score": 2,
                "score_justification": "The utterance goes beyond simple thanks by explicitly stating a significant learning outcome and strong appreciation, thereby fostering trust and validating the collaborative effort."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Good. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Good.' explicitly acknowledges and affirms Lisa's positive feedback about learning a lot and appreciating the discussion, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides a clear, positive acknowledgment of a team member's contribution, but it is brief and lacks further elaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Me too. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Me too' expresses shared positive sentiment and acknowledgment in response to Lisa's statement about learning a lot and appreciating the discussion, aligning with the Relational Climate code.",
                "score": 1,
                "score_justification": "The utterance provides a clear, explicit acknowledgment of shared positive sentiment, which is more than a token acknowledgment but not a strong, elaborated expression."
            }
        }
    },
    {
        "utterance": "Sixian You: Yeah, I learned all the all the dark size and potentially price size of therapy. What I learned again is biology is so hard and medicine is so hard. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Sixian expresses personal learning and a shared sentiment about the difficulty of biology and medicine, which acknowledges the value of the discussion and fosters a positive interpersonal tone.",
                "score": 2,
                "score_justification": "The utterance provides a strong personal reflection on learning from the discussion, which fosters a sense of shared understanding and appreciation for the complexity of their work, thereby building trust and a positive team climate."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: I really really liked what Crystal said about the communication being key as we do push forward with anything shiny and new. ",
        "annotations": {
            "Evaluation Practices": {
                "explanation": "Lisa expresses strong approval for Crystal's idea that communication is key, implicitly reasoning that it's crucial when pursuing new initiatives.",
                "score": 1,
                "score_justification": "The utterance provides a clear judgment of an idea ('communication being key') with some implicit reasoning for its importance in new endeavors."
            },
            "Relational Climate": {
                "explanation": "Lisa explicitly expresses strong positive sentiment ('I really really liked') towards Crystal's contribution, showing support and acknowledgment.",
                "score": 1,
                "score_justification": "The utterance offers explicit praise and interest in Crystal's point, clearly acknowledging and supporting her contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I totally agree. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "The utterance 'Yeah, I totally agree' expresses explicit agreement and support for Lisa's previous statement, contributing to a positive interpersonal tone.",
                "score": 1,
                "score_justification": "The utterance provides explicit agreement, which is a clear contribution to the relational climate, but it is not a highly elaborated or novel expression of support."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: And I liked what Molly said about the difficulty with integrating over time scales and and having tractable metrics for many of the different diseases. ",
        "annotations": {
            "Relational Climate": {
                "explanation": "Dylan expresses explicit appreciation for Molly's previous contribution regarding the difficulty of integrating over time scales and having tractable metrics, which aligns with expressing acknowledgment or support.",
                "score": 1,
                "score_justification": "The utterance clearly expresses appreciation for a specific point made by a team member, which is a clear contribution to the relational climate."
            }
        }
    }
]